[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 390
1. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol; 2009 Nov 10;27(32):5410-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
  • PURPOSE Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors.
  • On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated.
  • PATIENTS AND METHODS The initial cohort was limited to patients with cutaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sézary syndrome, who had received no more than two prior cytotoxic regimens.
  • These patients had undergone a median of four prior treatments, and 62 patients (87%) had advanced-stage disease (stage IIB, n = 15; stage III, n= 6; or stage IV, n = 41).
  • [MeSH-major] Depsipeptides / therapeutic use. Histone Deacetylase Inhibitors / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 1995 Jul;133(1):6-12 [7669641.001]
  • [Cites] Ann Intern Med. 1994 Oct 15;121(8):592-602 [8085692.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6791-6 [9618491.001]
  • [Cites] Exp Cell Res. 1998 May 25;241(1):126-33 [9633520.001]
  • [Cites] J Am Acad Dermatol. 1999 Mar;40(3):418-25 [10071312.001]
  • [Cites] J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):914-24 [10365922.001]
  • [Cites] Biol Pharm Bull. 2005 Jan;28(1):124-9 [15635176.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3697-702 [15738394.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):798-812 [15841167.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):428-34 [16112348.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3762-73 [16778104.001]
  • [Cites] Cancer J. 2007 Jan-Feb;13(1):30-9 [17464244.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):854-9 [17638728.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Apr 1;865(1-2):153-8 [18342585.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] Clin Lymphoma Myeloma. 2008 Aug;8(4):249-52 [18765314.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1496-503 [19228751.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6 [10922406.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):817-25 [10952788.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):718-28 [11895901.001]
  • [Cites] Leuk Lymphoma. 2002 Jun;43(6):1297-302 [12152999.001]
  • [Cites] J Exp Ther Oncol. 2002 Nov-Dec;2(6):325-32 [12440223.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):13-8 [12892709.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Dec;17(6):1367-89, viii [14710890.001]
  • [Cites] Curr Pharm Des. 2004;10(19):2289-98 [15279609.001]
  • [Cites] Cancer Treat Rep. 1979 Apr;63(4):725-8 [445521.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):372-82 [3408055.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Lancet. 1991 Feb 2;337(8736):268-9 [1671113.001]
  • [Cites] JAMA. 1992 Mar 11;267(10):1354-8 [1740857.001]
  • [Cites] J Antibiot (Tokyo). 1994 Mar;47(3):301-10 [7513682.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5705-8 [8650156.001]
  • (PMID = 19826128.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Depsipeptides; 0 / Histone Deacetylase Inhibitors; CX3T89XQBK / romidepsin
  • [Other-IDs] NLM/ PMC2773225
  •  go-up   go-down


2. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol; 2005 Aug 10;23(23):5347-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
  • PURPOSE: Mantle cell lymphoma (MCL) is characterized by a t(11;14) resulting in overexpression of cyclin D1 messenger RNA.
  • The median age was 70 years (range, 38 to 89 years), 91% were stage 4, and 69% had two or more extranodal sites.
  • [MeSH-major] Lymphoma, Mantle-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Sirolimus / analogs & derivatives

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15983389.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35090; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63826; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA97274; United States / PHS HHS / / CS-35431
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 136601-57-5 / Cyclin D1; 624KN6GM2T / temsirolimus; EC 2.7.11.1 / Ribosomal Protein S6 Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


3. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastava PK, Younes A: Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer; 2007 Jan 1;109(1):77-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.
  • BACKGROUND: The objective of this phase II trial was to investigate the safety and efficacy of autologous heat shock protein-peptide complex 96 (HSPPC-96) vaccines prepared from tumor specimens of patients with newly diagnosed or previously treated indolent non-Hodgkin lymphoma (NHL).
  • METHODS: The study was for patients with indolent B-cell NHL with measurable lesions.
  • Eighteen (90%) patients had stage III or IV disease.
  • One patient experienced a response with biopsy-proven clearance of the lymphoma cells in 2 of the skin nodules at 3.0 months that lasted for 7.0 months.
  • CONCLUSIONS: HSPPC-96 can be prepared from tumor specimens for the majority of lymphoma patients, but it had limited efficacy in inducing responses in patients with active diseases.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Heat-Shock Proteins / administration & dosage. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Clinical Trials, Phase II as Topic. Disease-Free Survival. Female. Humans. Injections, Intradermal. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17133412.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Heat-Shock Proteins; 492448-75-6 / vitespin
  •  go-up   go-down


Advertisement
4. Karadeniz C, Oguz A, Citak EC, Uluoglu O, Okur V, Demirci S, Okur A, Aksakal N: Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center. Pediatr Hematol Oncol; 2007 Sep;24(6):417-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center.
  • The aim of this study was to evaluate and compare the clinical characteristics of the B-cell non-Hodgkin lymphoma (NHL) patients and therapeutic efficacy of modified NHL BFM-90 and NHL BFM-95 protocols in the authors' center.
  • There were 14 patients in stage II, 28 in stage III, and 19 in stage IV.
  • Forty-five patients were treated with modified B-cell BFM-90 and 16 patients were treated with B-cell BFM-95 regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. SODIUM BICARBONATE .
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710659.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diuretics; 0 / Neoplasm Proteins; 5J49Q6B70F / Vincristine; 63CZ7GJN5I / Allopurinol; 8MDF5V39QO / Sodium Bicarbonate; EC 1.1.1.27 / L-Lactate Dehydrogenase; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Papaxoinis G, Fountzilas G, Rontogianni D, Dimopoulos MA, Pavlidis N, Tsatalas C, Pectasides D, Xiros N, Economopoulos T: Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol; 2008 Apr;19(4):780-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG).
  • BACKGROUND: The aim was to examine characteristics and treatment results of patients with mucosa-associated lymphoid tissue (MALT) non-Hodgkin's lymphomas.
  • PATIENTS AND METHODS: Epidemiological and clinical features of 97 patients with MALT lymphoma from the Hellenic Cooperative Oncology Group registry were analysed retrospectively for their prognostic significance in progression-free survival (PFS) and overall survival (OS).
  • Comparisons were made between patients with gastric and nongastric sites of primary lymphoma and between different therapeutic modalities.
  • Seventy-four per cent of patients had early (Ann Arbor stages I-II) and 26% had advanced (stages III-IV) disease.
  • The most reliable prognostic factor for PFS and OS was the Ann Arbor stage; 5-year PFS was 67% versus 13% and 5-year OS 91% versus 51% for patients with early versus advanced disease, respectively (P < 0.001).
  • Surgery did not offer survival benefit compared with chemotherapy in localised gastric lymphoma.
  • Ann Arbor stage was the most reliable prognostic and predictive factor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156143.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


6. Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, Ko YH, Ahn YC, Kim HJ, Suh C, Kim K, Kim WS: When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol; 2010 May;21(5):1058-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
  • BACKGROUND: The incidence and risk factors of central nervous system (CNS) invasion is still unclear in extranodal natural killer (NK)/T-cell lymphoma, nasal type.
  • PATIENTS AND METHODS: We analyzed 208 patients to study the clinical features and outcomes of CNS disease in extranodal NK/T-cell lymphoma.
  • The clinical variables associated with CNS disease were Ann Arbor stage III/IV (15.87%, P <0.001), regional lymph node involvement (10.41%, P = 0.006), group III/IV of NK/T-cell lymphoma prognostic index (NKPI; 10.20%, P = 0.003), high/high-intermediate international prognostic index (9.30%, P = 0.072) and extra-upper aerodigestive primary sites (9.75%, P = 0.008).
  • In multivariate analysis, NKPI retained the strongest statistical power to predict CNS disease (P = 0.007, relative risk 9.289, 95% confidence interval 1.828-47.212) in extranodal NK/T-cell lymphoma.
  • CONCLUSIONS: Despite extranodal NK/T-cell lymphoma frequently involves paranasal sinus, a routine CNS evaluation and prophylaxis do not seem to be necessary in NKPI group I or II patients due to a very low incidence.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850636.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Schwaiger M, Wieder H: Role of PET in lymphoma. Chang Gung Med J; 2005 May;28(5):315-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of PET in lymphoma.
  • In Hodgkin's lymphoma (HL), PET imaging should be performed in all patients, particularly in stage I or II disease where change in staging will alter management.
  • For aggressive Non-Hodgkin's lymphoma (NHL), PET imaging is valuable to provide a baseline for response evaluation.
  • [MeSH-major] Lymphoma / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Amino Acids / metabolism. Bone Marrow / pathology. Cell Proliferation. Fluorodeoxyglucose F18. Gallium Radioisotopes. Humans. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086546.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Gallium Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Hellmig S, Gieseler F, Ott S, Rosenstiel P, Fischbach W, Fölsch UR, Schreiber S: Germline variations of the topoisomerase IIalpha gene as risk factors for primary gastric B-cell lymphoma. Cancer Lett; 2006 Jul 18;238(2):295-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline variations of the topoisomerase IIalpha gene as risk factors for primary gastric B-cell lymphoma.
  • We investigated if germline variations of the Topoisomerase II alpha gene could predispose patients with chronic Helicobacter pylori infection to develop gastric lymphoma and conducted a mutation detection of the entire promoter region.
  • Single marker and haplotype analysis did not reveal any associations with development of gastric lymphoma in general, histological grade or stage of disease (P>0.05).
  • No genetic variations in the promotor region were found in 92 chromosomes of lymphoma patients and controls and linkage disequilibrium indicated a highly conserved genomic region.
  • The results of our work exclude genetic variations as predisposing factors of primary gastric B-cell lymphoma development.
  • [MeSH-major] Antigens, Neoplasm / genetics. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Lymphoma, B-Cell / genetics. Polymorphism, Single Nucleotide. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Female. Germ-Line Mutation. Haplotypes. Humans. Linkage Disequilibrium. Lymphoma, B-Cell, Marginal Zone / genetics. Male. Middle Aged. Molecular Sequence Data. Risk Factors

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16139951.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


9. Hurvitz SA, Timmerman JM: Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol; 2005 Sep;17(5):432-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
  • PURPOSE OF REVIEW: Therapeutic vaccines targeting B cell lymphoma idiotype have reached an advanced stage of clinical development, with three multicenter randomized clinical trials ongoing.
  • RECENT FINDINGS: Several groups have achieved promising results in phase II trials of patient-specific idiotype vaccines, with very few side effects noted.
  • A third trial opened in 2004, using rituximab followed by idiotype vaccine with maintenance booster vaccines continuing throughout the period of normal B cell recovery.
  • SUMMARY: Lymphoma idiotype vaccination represents a promising immunotherapeutic approach targeting a patient-specific tumor antigen.
  • Advanced manufacturing techniques should permit application of this tailor-made treatment to large numbers of non-Hodgkin's lymphoma patients.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Vaccines, DNA / therapeutic use
  • [MeSH-minor] Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Humans. Immunoglobulin Idiotypes / therapeutic use. Immunotherapy / trends

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093791.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Immunoglobulin Idiotypes; 0 / Vaccines, DNA
  • [Number-of-references] 82
  •  go-up   go-down


10. Hong J, Kim AJ, Park JS, Lee SH, Lee KC, Park J, Sym SJ, Cho EK, Shin DB, Lee JH: Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. Korean J Hematol; 2010 Dec;45(4):253-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis.
  • BACKGROUND: Standard treatment for stage I or non-bulky stage II diffuse large B-cell lymphoma (DLBCL) has been either a brief course of chemotherapy plus involved-field radiotherapy (IFRT) or prolonged cycles of chemotherapy.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2258-63 [18413640.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):787-92 [17228021.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1295-302 [2788716.001]
  • [Cites] Ann Intern Med. 1987 Jul;107(1):25-30 [3296898.001]
  • [Cites] Radiother Oncol. 1985 Nov;4(3):211-23 [3909240.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):1-7 [6406037.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2356-9 [7002279.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):197-204 [11773170.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 2003 Jul 1;102(1):324-7 [12649152.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2982-4 [15210737.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3032-8 [15210738.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:221-36 [15561685.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] BMC Cancer. 2010;10:321 [20569446.001]
  • (PMID = 21253427.001).
  • [ISSN] 2092-9129
  • [Journal-full-title] The Korean journal of hematology
  • [ISO-abbreviation] Korean J Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3023051
  • [Keywords] NOTNLM ; Diffuse large B-cell lymphoma / Radiotherapy / Rituximab
  •  go-up   go-down


11. Tang QL, Yang KZ, Liu WP, Peng ZL, Li JM, Li GD: [A clinicopathologic analysis of primary ovarian non-Hodgkin's lymphoma]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jul;37(4):641-3, 655
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinicopathologic analysis of primary ovarian non-Hodgkin's lymphoma].
  • OBJECTIVE: To observe the clinicopathologic manifestations and to investigate the clinicopathologic features and diagnosis of primary ovarian non-Hodgkin's lymphoma.
  • METHODS: A retrospective study of clinicopathology was made for 15 cases of primary ovarian non-Hodgkin's lymphomas.
  • RESULTS: This kind of tumor was accounted for 0.56% of all non-Hodgkin's lymphoma (NHL) received in the same period.
  • In all 15 cases, the patients of stage III and IV were 12 (80%), and stage I and II were 3 cases (20%).
  • Histological classification: all 15 cases (100%) were diffuse large B cell lymphoma (DLBCL), centroblast or immunoblast types.
  • CONCLUSION: Primary ovarian non-Hodgkin's lymphoma is rare and the prognosis is usually poor.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909622.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Lee J, Suh C, Kang HJ, Ryoo BY, Huh J, Ko YH, Eom HS, Kim K, Park K, Kim WS: Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol; 2008 Dec;19(12):2079-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
  • The aim of the study was to determine the maximum tolerated dose (MTD) and safety of the combination of bortezomib and cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) as first-line therapy in advanced, aggressive T-cell lymphoma.
  • Thirteen patients, who had stage III/IV chemonaive aggressive T-cell lymphoma, received a total of 55 cycles of treatment.
  • There was no dose-limiting non-hematologic toxicity.
  • Bortezomib can be safely combined with CHOP chemotherapy and constitutes an active regimen in advanced-stage, aggressive T-cell lymphoma patients.
  • The recommended dose for subsequent phase II studies of bortezomib plus CHOP is 1.6 mg/m(2)/dose of bortezomib on days 1 and 8 every 3 weeks as first-line treatment.

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3642-51 [17575229.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):971-9 [16557600.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3867-71 [18235046.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2505-11 [12171876.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):349-52 [11332147.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(1):75-81 [11750843.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1553-4 [12900354.001]
  • [Cites] Cancer Control. 2003 Sep-Oct;10(5):361-9 [14581890.001]
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):171-9 [15056047.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):230-7 [15072615.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2108-21 [15169797.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1783-90 [2585020.001]
  • [Cites] Ann Oncol. 1990;1(1):45-50 [1706610.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4514-20 [9192775.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1226-30 [15798768.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(10):1402-8 [15963893.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] Haematologica. 2006 Mar;91(3):427-8 [16503553.001]
  • [Cites] Blood. 2007 Jul 1;110(1):469-70 [17579189.001]
  • (PMID = 18689866.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 5J49Q6B70F / Vincristine; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.25.1 / Proteasome Endopeptidase Complex; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC2733119
  •  go-up   go-down


13. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, Verbois L, Morse DE, Jee JM, Pope S, Harapanhalli RS, Dagher R, Farrell A, Justice R, Pazdur R: Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res; 2007 Apr 15;13(8):2318-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
  • PURPOSE: To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL).
  • RESULTS: The pivotal trial enrolled 74 patients with stage IB or higher CTCL.
  • Median number of prior treatments was 3, and 61 patients (82%) had stage IIB or higher disease.
  • The objective response rate in the skin disease assessed by change in the overall SWAT score from the baseline was 30% (95% CI, 18.5 to 42.6) in patients with stage IIB or higher disease.
  • Median time to tumor progression was 148 days for overall population and 169 days for patients with stage IIB or higher disease.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Hydroxamic Acids / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy
  • [MeSH-minor] Animals. Cats. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Dogs. Humans. Neoplasm Staging. Patient Selection. Pruritus / drug therapy. Pruritus / etiology. Skin / drug effects. Skin / pathology. United States. United States Food and Drug Administration

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Hazardous Substances Data Bank. Vorinostat .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438089.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  •  go-up   go-down


14. Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA: Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol; 2005 Mar;74(3):194-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands.
  • OBJECTIVE: To determine the incremental cost-effectiveness ratio (ICER) of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) vs. CHOP plus rituximab (R-CHOP) in diffuse large B-cell lymphoma (DLBCL) patients in the Netherlands.
  • METHODS: A state transition model was developed to estimate the clinical course, costs and quality of life of patients with stage II, III or IV DLBCL receiving initial treatment with CHOP or R-CHOP to arrive at the ICER.
  • [MeSH-major] Antibodies, Monoclonal / economics. Lymphoma, Large B-Cell, Diffuse / economics
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / economics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Budgets. Cost-Benefit Analysis. Decision Making. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / economics. Lymphoma, B-Cell / mortality. Monte Carlo Method. Netherlands. Quality of Life. Rituximab. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693788.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


15. Laskar S, Muckaden MA, Bahl G, de S, Nair R, Gupta S, Bakshi A, Prabhash K, Maru D, Gujral S, Parikh P, Shrivastava SK, Dinshaw KA: Primary non-Hodgkin's lymphoma of the nasopharynx: prognostic factors and outcome of 113 Indian patients. Leuk Lymphoma; 2006 Oct;47(10):2132-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the nasopharynx: prognostic factors and outcome of 113 Indian patients.
  • This single institutional study evaluated the prognostic factors and treatment outcome of 113 Indian patients with primary nasopharyngeal non-Hodgkin's lymphoma.
  • At presentation, 28% had stage I and 62% had stage II disease.
  • Multivariate analysis showed that; age > 30 years [hazard ratio (HR) = 6.59, 95% confidence interval (CI) = 2.59 - 16.7, P < 0.0001], WHO performance score > or = 2 (HR = 2.34, 95% CI = 1.01 - 5.46, P = 0.050), T-cell lymphomas (HR = 2.81, 95% CI = 1.14 - 6.96, P < 0.001) and the presence of B symptoms (HR = 3.65, 95% CI = 1.77 - 7.53, P = 0.025), had a negative influence on survival.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Nasopharyngeal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071487.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Chen CQ, Yin L, Peng CH, Zhao R, Chen GM, Zhou HJ, Li HW: [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases].
  • OBJECTIVE: To study the clinical characteristics,treatment and prognosis of primary non-Hodgkin's lymphoma of small bowel.
  • METHODS: The records of 34 patients with a confirmed diagnosis of primary non-Hodgkin's lymphoma of small bowel, registered between Jan.
  • RESULTS: Twenty-seven patients had B-cell lymphoma and 7 had T-cell lymphoma of the small bowel.
  • According to Ann Arbor staging classification, 22 patients belonged to stage I~II, including 20 cases of B-cell lymphoma and 2 cases of T-cell lymphoma, and 12 patients belonged to stage III~IV, including 7 cases of B-cell lymphoma and 5 cases of T-cell lymphoma.
  • Compared with T-cell lymphoma patients, B-cell lymphoma patients had lower lymphoma stages (P<0.05).
  • T-cell lymphoma patients were more often treated with emergent operation than B-cell lymphoma patients would (P<0.05).
  • It happened more frequently that B-cell lymphoma patients reached complete remission and their accumulative survival rate was longer than T-cell lymphoma patients did (P<0.05).
  • CONCLUSION: Patients with stages I and II B-cell lymphoma of small bowel respond well to surgery and chemotherapy, and the treatment and prognosis of patients with T-cell lymphoma of small bowel are unsatisfactory.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies


17. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N: Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma; 2006 Jul;7(1):51-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
  • PURPOSE: The purpose of this study was to investigate safety and efficacy of gemcitabine monotherapy for cutaneous T-cell lymphoma (CTCL).
  • PATIENTS AND METHODS: Twenty-five patients with CTCL on a phase II open-label trial and 8 patients off study received intravenous gemcitabine (1000 mg/m2) on day 1, 8, and 15 for > or = 6 cycles.
  • RESULTS: Two patients with CD30+ anaplastic large T-cell lymphoma and 31 with mycosis fungoides (stage IB [T2, n = 2], stage IIA [T2, n = 1], stage IIB [T3, n = 13], stage IVA [T3 N3, n = 3; T4b2, n = 2; T4b2 N3, n = 2], and stage IVB [T4b2 N1, n = 6; T4 N3b2 M1, n = 1; T3 N3 M1, n = 1]) had received a median of 5 previous therapies (range, 1-13 therapies).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma, T-Cell, Cutaneous / drug therapy. Sezary Syndrome / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879770.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672-22; United States / NCI NIH HHS / CA / K24 CA 86815
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Interleukin-2; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


18. Quereux G, Marques S, Nguyen JM, Bedane C, D'incan M, Dereure O, Puzenat E, Claudy A, Martin L, Joly P, Delaunay M, Beylot-Barry M, Vabres P, Celerier P, Sasolas B, Grange F, Khammari A, Dreno B: Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol; 2008 Jun;144(6):727-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the rate of objective response to pegylated liposomal doxorubicin hydrochloride (Caelyx) in patients with advanced or refractory cutaneous T-cell lymphoma (CTCL).
  • PATIENTS: Twenty-five patients with either (1) stage II to stage IV CTCL previously unsuccessfully treated with at least 2 lines of treatments or (2) histologically transformed epidermotropic CTCL requiring chemotherapy.
  • CONCLUSIONS: This prospective study demonstrates the effectiveness of Caelyx in treating CTCL, with an overall response rate of 56% in spite of the high proportion of patients with advanced-stage disease.

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2008 Jun;144(6):786-7 [18559771.001]
  • (PMID = 18559761.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


19. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H: Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum; 2005 Sep;52(9):2740-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
  • OBJECTIVE: To investigate the safety and efficacy of B cell depletion treatment of patients with active primary Sjögren's syndrome of short duration (early primary SS) and patients with primary SS and mucosa-associated lymphoid tissue (MALT)-type lymphoma (MALT/primary SS).
  • METHODS: Fifteen patients with primary SS were included in this phase II trial.
  • Inclusion criteria for the early primary SS group were B cell hyperactivity (IgG >15 gm/liter), presence of autoantibodies (IgM rheumatoid factor, anti-SSA/SSB), and short disease duration (<4 years).
  • Inclusion criteria for the MALT/primary SS group were primary SS and an associated MALT-type lymphoma (Ann Arbor stage IE) localized in the parotid gland.
  • CONCLUSION: Findings of this phase II study suggest that rituximab is effective in the treatment of primary SS.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Sjogren's Syndrome / drug therapy

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142737.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


20. Forns M, Javier G, Estella J, Fernández-Delgado R, Gallego S, García-Miguel P, Indiano JM, Navajas A, Pardo N, en representación del grupo SHOP de las Sociedades Españolas de Hematología (SEHP) y Oncología Pediátricas (SEOP): [Results of the SHOP LNHB98 (LMB89) trial in pediatric patients with B-cell non-Hodgkin's lymphoma]. Med Clin (Barc); 2007 May 5;128(17):641-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of the SHOP LNHB98 (LMB89) trial in pediatric patients with B-cell non-Hodgkin's lymphoma].
  • [Transliterated title] Resultados del protocolo SHOP LNHB98 (LMB89) en pacientes de edad pediátrica afectados de linfoma no hodgkiniano de células B.
  • BACKGROUND AND OBJECTIVE: After the good results obtained by the Société Française d'Oncologie Pédiatrique (SFOP) regarding the pediatric B-type non-Hodgkin's (Burkitt and large B-cell) lymphoma and L3 leukemia, the Sociedad Española de Hematología y Oncología Pediátricas (SHOP) decided to use the same treatment protocol.
  • PATIENTS AND METHOD: Pediatric patients diagnosed with B-type non-Hodgkin's lymphoma without a previous history of malignant diseases were eligible for this study.
  • They were classified in 3 groups of risk: group A (resected stage I and abdominal stage II), group B (not eligible for groups A or C), and group C (with central nervous system involvement and L3 leukemia).
  • RESULTS: A total of 153 patients were considered in this multicenter, prospective and non-randomized trial (1997-2005).
  • CONCLUSIONS: The results confirm the good efficiency of the LMB89 protocol for treating B-cell lymphoma and L3 leukemia, despite having diminished the treatment intensity in the less risk groups.
  • In addition, no differences were evidenced between Burkitt and large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537360.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Spain
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; LMB89 protocol
  •  go-up   go-down


21. Beltran B, Castillo J, Salas R, Quiñones P, Morales D, Hurtado F, Riva L, Winer E: ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol; 2009;2:11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.
  • BACKGROUND: Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL) is a rare lymphoma with several clinicopathological differences from ALK-positive anaplastic large cell lymphoma (ALCL).
  • Stages were I (n = 1), II (n = 1), III (n = 1) and IV (n = 1).
  • The survival for the patients with stage I, II, III and IV were 13, 62, 72 and 11 months, respectively.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / metabolism. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2009 Jan;40(1):75-82 [18755494.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Am J Clin Pathol. 2001 Mar;115(3):396-403 [11242796.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1285-8 [15492998.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Pol J Pathol. 2005;56(1):37-45 [15921012.001]
  • [Cites] Curr Oncol Rep. 2005 Sep;7(5):357-63 [16091196.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1839-40 [16107887.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):390-1 [16086416.001]
  • [Cites] Rinsho Ketsueki. 2005 Jul;46(7):501-6 [16440742.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):649-53 [15852431.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):493-505 [16794633.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2006 Sep;35(9):529-34 [17134546.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):940-5 [17509395.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):166-9 [17635242.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2573-80 [18089849.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):126-44 [18039352.001]
  • [Cites] Korean J Lab Med. 2008 Apr;28(2):89-94 [18458503.001]
  • [Cites] Biochem J. 2008 Jun 15;412(3):415-23 [18498251.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):108-13 [18220322.001]
  • (PMID = 19250532.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 39
  • [Other-IDs] NLM/ PMC2651189
  •  go-up   go-down


22. Frassoni F, Gualandi F, Podestà M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, Labopin M, Bacigalupo A: Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol; 2008 Sep;9(9):831-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study.
  • The aim of this phase I/II study was to establish the safety and efficacy of a new administration route (intrabone) for cord-blood cells, measured by the donor-derived neutrophil and platelet engraftment.
  • METHODS: Adult patients with acute leukaemia, for whom an unrelated stem-cell transplantation was indicated and no suitable unrelated human leucocyte antigen (HLA)-matched donor had been identified, were included in the study and underwent a cord-blood transplant in San Martino Hospital, Genoa, Italy.
  • Eight patients were in first complete remission, ten in second complete remission, and 14 had advanced-stage, refractory disease.
  • Median transplanted cell dose was 2.6 x 10(7)/kg (range 1.4-4.2).
  • Four patients with advanced-stage disease died within 12 days of the procedure.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


23. De Cicco L, Cella L, Liuzzi R, Solla R, Farella A, Punzo G, Tranfa F, Strianese D, Conson M, Bonavolontà G, Salvatore M, Pacelli R: Radiation therapy in primary orbital lymphoma: a single institution retrospective analysis. Radiat Oncol; 2009;4:60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy in primary orbital lymphoma: a single institution retrospective analysis.
  • BACKGROUND: Primary orbital lymphoma is a rare disease that accounts for 10% of all orbital tumors.
  • Radiotherapy on the orbital cavity is the treatment of choice for this unusual presentation of localized non-Hodgkin's lymphoma (NHL).
  • The aim of this study is to retrospectively evaluate the effectiveness and the toxicity of radiation treatment in patients with primary orbital lymphoma.
  • METHODS: Forty-seven consecutive patients having primary orbital lymphoma treated in our department between May 1983 and September 2006 were investigated in a retrospective study.
  • Forty-three patients had stage IE, three had stage II and one stage IV disease.
  • Thirty-eight patients had marginal zone B-cell lymphoma, 5 diffuse large B cell lymphoma, 3 mantle cell lymphoma and 1 Burkitt lymphoma.
  • CONCLUSION: Radiotherapy is an effective and at the same time well tolerated treatment for primary orbital lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Orbital Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 May;59(2):139-44 [11325441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):86-91 [19632068.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):657-63 [11849787.001]
  • [Cites] Orbit. 2002 Jun;21(2):117-23 [12029566.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):818-23 [12377334.001]
  • [Cites] Surv Ophthalmol. 2002 Sep-Oct;47(5):470-90 [12431695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):892-8 [12605966.001]
  • [Cites] Strahlenther Onkol. 2003 Jun;179(6):396-400 [12789466.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):865-71 [12910532.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):172-6 [12909230.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1382-91 [14630277.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):527-30 [15380588.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Strahlentherapie. 1982 Sep;158(9):520-3 [6183800.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jul;10(7):1013-9 [6430846.001]
  • [Cites] Radiother Oncol. 1991 Sep;22(1):36-44 [1947211.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):59-66 [8482631.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):703-7 [8033051.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):929-34 [7860408.001]
  • [Cites] Radiother Oncol. 1996 Jan;38(1):13-8 [8850421.001]
  • [Cites] Tumori. 1997 Sep-Oct;83(5):822-5 [9428915.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):31-6 [10219791.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):13-8 [15309523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):866-71 [15925453.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):228-33 [16503386.001]
  • [Cites] Ophthalmology. 2006 Jul;113(7):1209-13 [16647129.001]
  • [Cites] Oncology. 2006;70(3):173-6 [16763405.001]
  • [Cites] Strahlenther Onkol. 2007 Jan;183(1):17-22 [17225941.001]
  • [Cites] Expert Opin Pharmacother. 2007 Jun;8(8):1073-83 [17922636.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):242-6 [17947227.001]
  • [Cites] Radiother Oncol. 2009 Feb;90(2):236-41 [18950885.001]
  • [Cites] Indian J Ophthalmol. 2009 Mar-Apr;57(2):91-7 [19237780.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):145-51 [11325442.001]
  • (PMID = 19968864.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2794866
  •  go-up   go-down


24. Ishikura S, Tobinai K, Ohtsu A, Nakamura S, Yoshino T, Oda I, Takagi T, Mera K, Kagami Y, Itoh K, Tamaki Y, Suzumiya J, Taniwaki M, Yamamoto S: Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach. Cancer Sci; 2005 Jun;96(6):349-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach.
  • CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) followed by radiotherapy is regarded as standard care for localized aggressive lymphoma; however, prospective confirmation of its applicability to localized primary gastric lymphoma is inadequate, and most patients in Japan have been initially treated with gastrectomy.
  • We conducted a multicenter phase II study to evaluate the feasibility and efficacy of the non-surgical treatment.
  • Eligibility criteria required primary gastric diffuse large B-cell lymphoma, stage I-II(1), age 20-75, performance status 0-1 and adequate organ function.
  • Patient characteristics were as follows: median age, 61 years; 28 men, 24 women; 36 with stage I, 16 with stage II(1); 47 with a low International Prognostic Index (IPI) and five with a low-intermediate IPI.
  • CHOP followed by radiotherapy is safe and highly effective in localized gastric diffuse large B-cell lymphoma.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958057.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


26. Weide R, Hess G, Köppler H, Heymanns J, Thomalla J, Aldaoud A, Losem C, Schmitz S, Haak U, Huber C, Unterhalt M, Hiddemann W, Dreyling M, German Low Grade Lymphoma Study Group: High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma; 2007 Jul;48(7):1299-306
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
  • On the basis of a preceding phase I study, the current trial explored bendamustine in combination with mitoxantrone and rituximab (BMR) in patients with stage III/IV relapsed or refractory indolent lymphomas and mantle cell lymphoma (MCL) with or without prior rituximab containing chemo-immunotherapy (R-chemo) treatment.
  • Lymphoma subtypes were 29 follicular (FL), 18 MCL, and 10 other indolent lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Nitrogen Mustard Compounds / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Bendamustine Hydrochloride. Female. Humans. Lymphoma, Follicular / complications. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / mortality. Male. Middle Aged. Mitoxantrone / administration & dosage. Remission Induction. Rituximab. Salvage Therapy / methods. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Jul;48(7):1264-6 [17613752.001]
  • (PMID = 17613757.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Nitrogen Mustard Compounds; 4F4X42SYQ6 / Rituximab; 981Y8SX18M / Bendamustine Hydrochloride; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


27. Geffen DB, Cagnano E, Tokar M, Ariad S, Koretz M: Ipsilateral breast carcinoma following treatment for primary breast lymphoma. Onkologie; 2007 Mar;30(3):134-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ipsilateral breast carcinoma following treatment for primary breast lymphoma.
  • BACKGROUND: The breast is an unusual site for primary non-Hodgkin's lymphoma.
  • Carcinoma in the same breast after treatment for lymphoma poses therapeutic challenges, but there is only 1 case report in Japanese, which describes this occurrence.
  • PATIENT AND METHODS: A 59-year-old woman was diagnosed with infiltrating ductal carcinoma of the breast after receiving doxorubicinand vincristine-based chemotherapy for ipsilateral primary large cell breast lymphoma.
  • CONCLUSION: Breast cancer can occur after breast lymphoma.
  • For primary breast lymphoma, cumulative doses of cardiotoxic and neurotoxic drugs should be limited to 3-4 cycles of chemotherapy, using treatment protocols for stage I-II large cell lymphoma.
  • [MeSH-major] Carcinoma, Ductal / diagnosis. Carcinoma, Ductal / therapy. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17341900.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


28. Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A, Sposto R, McCarthy K, Lacombe MJ, Perkins SL, Patte C, FAB LMB96 International Study Committee: Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol; 2008 Jun;141(6):840-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
  • High cure rates are possible in children with localized mature B-cell lymphoma (B NHL) using a variety of chemotherapeutic strategies.
  • The Lymphome Malins de Burkitt (LMB) 89 study reported long-term survival in almost all children with localized resected disease treated with two courses of COPAD (cyclophosphamide, vincristine, prednisolone and doxorubicin).
  • Patients in this part of the study had resected stage I or completely resected abdominal stage II disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18371107.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; COPAD protocol
  • [Investigator] Patte C; Brugieres L; Grill J; Hartmann O; Kalifa C; Oberlin O; Pein F; Valteau D; Nelken B; Mazingue F; Behrendt H; Zsiros J; Michon J; Zucker JM; Doz F; Pacquement H; Quintana E; Robert A; Rubie H; Bertozzi AI; Bertrand Y; Pondarré C; Coze C; Gentet JC; Michel G; Mechinaud F; Thomas C; Suarez A; Perel Y; Notz A; Leverger G; Landmann-Parker J; Tabone D; Chastagner D; Schmitt C; Legall E; Edan C; Gandemer V; Margeritte G; Bernard JL; Vilmer E; Rohrlich P; Frapppaz D; Bergeron C; Marrec P; Vannier JP; Sirvens N; Deville A; Soler C; Millot F; Devalck C; Sariban E; Lutz P; Babin Boilletot A; Plantaz D; Baruchel A; Leblanc T; Behar C; Lamagnere JP; Lejars O; Demeocq F; Plouvier E; Laitier V; Boutard P; Minckes O; Pautard B; De Lumley L; Francotte-lempereur N; Michalski A; Chisholm J; Chessells J; Daw S; Webb D; Pritchard J; Stevens M; Grundy R; Mann J; Morland B; Mellor S; Pinkerton R; Pritchard-Jones K; Picton S; Lewis I; Richards R; Anninga J; Bouffet E; Kirby M; Estlin E; Lowis S; Foot A; Breatnach F; O'Meara A; Windebank K; Jenney M; Brennan B; Eden T; Simpson E; Chalmers E; Kohler J; Radford M; Bevan S; Gerrard M; Kilby A; Michelagnoli M; Jenney M; English M; McDowell H; Pizer B; Dempsey S; Mitchell C; Wheeler K; Wallace H; Williams D; Broadbent V; Nicholson J; Kingston J; Shankar A; King D; Hewitt M; Walker D
  •  go-up   go-down


29. Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP, Southwest Oncology Group: Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol; 2008 May 10;26(14):2258-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
  • PURPOSE: To evaluate the effect of rituximab in limited-stage diffuse large B-cell lymphoma (DLBCL), we conducted a multicenter phase II trial combining rituximab with three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP) followed by involved-field radiation therapy (IFRT).
  • PATIENTS AND METHODS: Southwest Oncology Group (SWOG) study S0014 enrolled patients with newly diagnosed, aggressive, CD20-expressing non-Hodgkin's lymphoma (NHL).
  • Patients had limited-stage disease and at least one adverse risk factor as defined by the stage-modified International Prognostic Index (nonbulky stage II disease, age > 60 years, WHO performance status of 2, or elevated serum lactate dehydrogenase).
  • CONCLUSION: In limited-stage DLBCL, the addition of rituximab to three cycles of CHOP plus IFRT met prespecified study criteria of efficacy, with 2-year PFS of at least 84%, meriting further investigation.
  • We hypothesize that such a pattern may be the result of biologic differences between limited- and advanced-stage lymphoma.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413640.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA04919
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


30. Banklau C, Jindadamrongwech S, Sawangpanich R, Apibal S, Hongeng S, Paisooksantivatana K, Pakakasama S: Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia. Hematol Oncol Stem Cell Ther; 2010;3(3):103-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: We included children diagnosed with ALL and lymphoblastic lymphoma (LL) stage III and IV.
  • The patients received a modified St Jude Total Therapy Study XV protocol.
  • Cytarabine was used during induction remission (low-dose cytarabine) and reinduction II (high-dose cytarabine) phases.
  • [MeSH-major] Cytarabine / therapeutic use. Cytidine Deaminase / genetics. Deoxycytidine Kinase / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890066.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 2.7.1.74 / Deoxycytidine Kinase; EC 3.1.3.48 / Antigens, CD45; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


31. Yang W, Lv S, Liu X, Liu H, Yang W, Hu F: Up-regulation of Tiam1 and Rac1 correlates with poor prognosis in hepatocellular carcinoma. Jpn J Clin Oncol; 2010 Nov;40(11):1053-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: T-cell lymphoma invasion and metastasis 1 (Tiam1) specifically activates Rho-like GTPases (e.g.
  • METHODS: Expression of Tiam1 and Rac1 was assessed in 242 hepatocellular carcinoma tissues and their adjacent normal hepatic tissues by performing immunohistochemistry and was gauged regarding stage, grade and survival.
  • RESULTS: Immunohistochemistry showed that patients with a high clinical stage hepatocellular carcinoma (III-IV) and α-fetoprotein levels had a higher tendency to express Tiam1 and Rac1 on tumor cells than the patients with low pathologic grade hepatocellular carcinoma (I-II) (P = 0.008 and 0.01, respectively) and low α-fetoprotein levels (P = 0.006 and 0.002, respectively).

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20522449.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Guanine Nucleotide Exchange Factors; 0 / RAC1 protein, human; 0 / TIAM1 protein, human; 0 / alpha-Fetoproteins; EC 3.6.5.2 / rac1 GTP-Binding Protein
  •  go-up   go-down


32. Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW: Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol; 2005 Sep;55(3):231-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Older patients (with serious co-morbidity) with non-small cell lung cancer or prostate cancer underwent surgery less often than younger patients.
  • Elderly with stage III colon cancer, small cell lung cancer, FIGO II or III ovarian cancer or non-Hodgkin's lymphoma (NHL) received (adjuvant) chemotherapy less often, probably because of the higher rate of haematological complications.
  • Administration of adjuvant radiotherapy decreased with age and co-morbidity in patients with rectal cancer, limited small cell lung cancer or breast cancer.
  • In general, elderly did not suffer from more complications than younger patients, except for cardiac complications (colorectal cancer and NHL) and postoperative death (non-small cell lung cancer).

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979890.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


33. Li YX, Liu QF, Fang H, Qi SN, Wang H, Wang WH, Song YW, Lu J, Jin J, Wang SL, Liu YP, Lu N, Liu XF, Yu ZH: Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res; 2009 Apr 15;15(8):2905-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma.
  • PURPOSE: To determine the clinical characteristics, prognosis, and treatment outcome for patients with nasal natural killer (NK)/T-cell lymphoma (N-NKTL) and Waldeyer ring NK/T-cell lymphoma (WR-NKTL).
  • Patients with stage II WR-NKTL showed favorable prognosis compared with those with stage II N-NKTL.
  • Compared with radiotherapy alone, patients with early-stage WR-NKTL that received radiotherapy and chemotherapy showed a superior progression-free survival and improved overall survival.
  • In contrast, the addition of chemotherapy to radiotherapy did not provide any survival benefit for patients with early-stage N-NKTL.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, Extranodal NK-T-Cell / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318493.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Beltran Gárate B, Morales Luna D, Quiñones Avila P, Hurtado de Mendoza F, Riva Gonzales L, Yabar A, Portugal Meza K: [Primary colorectal lymphoma of diffuse large B-cells: an experience at a general hospital]. Rev Gastroenterol Peru; 2008 Jul-Sep;28(3):235-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary colorectal lymphoma of diffuse large B-cells: an experience at a general hospital].
  • [Transliterated title] Linfoma de células grandes B difuso primario colorectal: experiencia en un hospital general.
  • Primary colorectal lymphoma is a very rare disease.
  • Primary colorectal lymphoma of diffuse large B-cells is a more frequent subtype representing 1% of all colon diseases.
  • In a retrospective study, the clinical characteristics and treatment course of primary colorectal lymphoma of diffuse large B-cells between 1997 and 2003 were reviewed.
  • Six were in Stage I, four in Stage II and four in Stage III.
  • The 5-year survival per stage was 26, 11 and 5 months, respectively.
  • Primary colorectal lymphoma of diffuse large B-cells usually affects the right part of the colon in an aggressive manner.
  • [MeSH-major] Colorectal Neoplasms. Lymphoma, Large B-Cell, Diffuse

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958138.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Peru
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


35. Hesseling P, Broadhead R, Mansvelt E, Louw M, Wessels G, Borgstein E, Schneider J, Molyneux E: The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer; 2005 Mar;44(3):245-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 2000 Burkitt lymphoma trial in Malawi.
  • BACKGROUND: We previously reported 57% 12-month event free survival (EFS) in Malawian children with stage I to III Burkitt lymphoma (BL) with an intermediate dose chemotherapy protocol lasting 77 days.
  • This protocol was shortened to 42 days and evaluated in children with stage I to IV disease for EFS and toxicity.
  • A fine needle aspirate, bone marrow aspirate, cerebrospinal fluid cytology, haemoglobin (Hb), white cell count (WCC), malaria smear, ELISA for HIV, and abdominal ultrasound were performed routinely.
  • The first dose of chemotherapy (COP1) consisted of 300 mg cyclophosphamide (CPM), 1 mg vincristine, and 60 mg prednisone given on day 1 and followed by COP2 on day 8 (only for patients with larger tumour volumes, stage III or IV disease).
  • RESULTS: Forty-two patients, 30 boys and 12 girls median ages 6 and 7.5 years, respectively, had Murphy stage I(n5), II(n8), III(n21), and IV(n8) disease.
  • The projected EFS at 12 months is 50% in stage I, 50% in stage II, 24% in stage III, 25% in stage IV, and 33% for all patients.
  • [MeSH-major] Burkitt Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Malaria and HIV .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15547922.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


36. Lee J, Suh C, Huh J, Jun HJ, Kim K, Jung C, Park K, Park YH, Ko YH, Kim WS: Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin Cancer Res; 2007 Jun 1;13(11):3250-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type.
  • PURPOSE: The aim of the study was to determine the effect of EBV-encoded RNA-1 in situ hybridization (EBER-1 ISH) in bone marrow specimens on survival outcome in patients with clinical stage I/II natural killer/T-cell lymphoma.
  • EXPERIMENTAL DESIGN: We systematically did EBER-1 ISH on 182 archival bone marrow tissues from 91 patients who were diagnosed of stage I/II natural killer/T-cell lymphoma and analyzed the correlation between bone marrow EBER-1 ISH status and survival.
  • CONCLUSION: Considering a high proportion of stage I/II patients (15.4%) with minimal in bone marrow specimens, bone marrow EBER-1 ISH should be routinely done in all patients with localized disease for more accurate staging.
  • [MeSH-major] Bone Marrow / virology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / metabolism. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / virology. Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / virology. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545530.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3
  •  go-up   go-down


37. Belgaumi AF, Al-Kofide A, Sabbah R, Shalaby L: Precursor B-cell lymphoblastic lymphoma (PBLL) in children: pattern of presentation and outcome. J Egypt Natl Canc Inst; 2005 Mar;17(1):15-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic lymphoma (PBLL) in children: pattern of presentation and outcome.
  • PURPOSE AND BACKGROUND: Precursor B-cell lymphoblastic lymphoma (PBLL) is a rare subtype of NHL seen primarily in children or young adults.
  • RESULTS: Twenty one patients were treated for lymphoblastic lymphoma, of which six had a precursor Bcell phenotype.
  • Four of the patients had limited stage disease (2 stage I and stage II), while 2 were stage IV.
  • Both patients with stage IV disease had CNS involvement with blasts in the CSF.
  • Five patients were treated according to B-cell NHL type protocols.
  • CONCLUSION: PBLL is a distinct B-cell NHL which involves extralymphatic sites, with particular predisposition for the upper aerodigestive tract.
  • Patients should not be treated on short intensive protocols used for other B-cell NHL but should receive treatment based on ALL protocols like those for treating T-cell LL.
  • [MeSH-major] B-Lymphocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353078.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


38. D'Angelo V, Crisci S, Casale F, Addeo R, Giuliano M, Pota E, Finsinger P, Baldi A, Rondelli R, Abbruzzese A, Caraglia M, Indolfi P: High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases. J Exp Clin Cancer Res; 2009;28:39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies on activated cell-signaling pathways responsible for neoplastic transformation are numerous in solid tumors and in adult leukemias.
  • The aim of this study was to asses the expression and activation status of crucial proteins involved in cell-signaling pathways in order to identify molecular alterations responsible for the proliferation and/or escape from apoptosis of leukemic blasts.
  • The quantitative and qualitative expression and activation of Erk-1, c-Jun, Caspase8, and Gadd45a was analyzed, by immunocytochemical (ICC) and western blotting methods, in bone marrow blasts of 72 patients affected by acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (ALL) and stage IV non-Hodgkin Lymphoma (NHL).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Cycle Proteins / metabolism. Lymphoproliferative Disorders / metabolism. Lymphoproliferative Disorders / pathology. Mitogen-Activated Protein Kinase 3 / metabolism. Nuclear Proteins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 May;14(5):786-91 [10803507.001]
  • [Cites] Leukemia. 2008 Apr;22(4):686-707 [18337767.001]
  • [Cites] J Clin Invest. 2001 Sep;108(6):851-9 [11560954.001]
  • [Cites] J Cell Biochem. 2002;84(4):675-86 [11835393.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5897-901 [12384554.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):123-8 [12469194.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Oct 15;146(2):89-101 [14553942.001]
  • [Cites] Leukemia. 2004 Feb;18(2):189-218 [14737178.001]
  • [Cites] Cancer Biol Ther. 2004 May;3(5):470-6 [15034294.001]
  • [Cites] Br J Haematol. 1981 Apr;47(4):553-61 [6938236.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90 [10451443.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4899-907 [10490824.001]
  • [Cites] Oncol Rep. 2004 Dec;12(6):1201-7 [15547738.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2047-53 [15781610.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):32-8 [15684603.001]
  • [Cites] Blood. 2005 Jul 15;106(2):408-18 [15797997.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6780-8 [16061660.001]
  • [Cites] Oncogene. 2005 Nov 3;24(48):7170-9 [16170381.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):17552-8 [16636063.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2358-65 [16763210.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5473-6 [17351113.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15537-46 [11297525.001]
  • (PMID = 19298651.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GADD45A protein, human; 0 / Nuclear Proteins; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / Caspase 8
  • [Other-IDs] NLM/ PMC2664791
  •  go-up   go-down


39. Cui XZ, Wang HQ, Liu XM, Zhang HL, Li W: [Treatment outcome and prognosis of autologous hematopoietic stem cell transplantation combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2007 Sep;28(9):609-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment outcome and prognosis of autologous hematopoietic stem cell transplantation combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma].
  • OBJECTIVE: To analyze the outcome and prognosis of autologous hematopoietic stem cell transplantation (AHSCT) combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma.
  • METHODS: From July 1992 to December 2005, 22 patients with nasal NK/T cell lymphoma were diagnosed pathologically.
  • The patients received cycles of chemotherapy every other two weeks or combined with radiotherapy for remission induction, followed high dose radiotherapy/chemotherapy, combined with autologous peripheral blood stem cell transplantation (APBSCT), or autologous bone-marrow transplantation (ABMT).
  • The 5-year OS were as follows: for stage I - II and III - IV disease were 90.0% and 70.0% (P = 0.
  • Multivariate analysis by COX regression revealed that disease stage, B symptom and IPI were independent prognostic factors.
  • CONCLUSION: AHSCT combined with high dose radiotherapy/chemotherapy is an effective treatment for patients with poor prognosis nasal NK/T cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Extranodal NK-T-Cell / therapy. Nose Neoplasms / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246818.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


40. van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group: Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol; 2005 Jun 1;23(16):3793-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
  • PURPOSE: Timing, appropriate amount, and composition of treatment before high-dose therapy and autologous stem-cell transplantation (ASCT) in patients with poor-risk, aggressive non-Hodgkin's lymphoma (NHL) are still unknown.
  • We conducted two consecutive multicenter phase II trials with up-front, high-dose, sequential chemotherapy and ASCT in poor-risk, aggressive NHL.
  • PATIENTS AND METHODS: Between 1994 and 2001, 147 newly diagnosed, poor-risk, aggressive NHL patients, age < or = 65 years with stage III to IV and lactate dehydrogenase (LDH) more than 1.5x upper limit of normal (ULN), entered the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) -27 and HOVON-40 trials.
  • RESULTS: Patient characteristics in both trials were comparable: 80% had diffuse large B-cell lymphoma, 77% had stage IV disease, and median LDH levels were 3.1x ULN.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisone / administration & dosage. Prognosis. Remission Induction. Risk Factors. Stem Cell Transplantation. Survival Rate. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809447.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


41. Vose JM, Weisenburger DD, Loberiza FR, Arevalo A, Bast M, Armitage J, Bierman PJ, Bociek RG, Armitage JO: Late relapse in patients with diffuse large B-cell lymphoma. Br J Haematol; 2010 Nov;151(4):354-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late relapse in patients with diffuse large B-cell lymphoma.
  • The outcomes for 162 patients with diffuse large B-cell lymphoma treated with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like regimen who obtained a complete remission and who subsequently relapsed after ≥5 years of remission (late relapse, N=30), or <5 years of remission (early relapse, N=132), were compared.
  • The late relapsing patients had better prognostic characteristics at diagnosis, such as stage I/II disease (73% vs. 49%, P=0·04), a normal lactic dehydrogenase (77% vs. 48%, P=0·01), and a Karnofsky performance score of ≥80 (100% vs. 86%, P=0·01).
  • However, the overall survival from the time of relapse was not different between early and late relapsing patients with most succumbing to lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20880118.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 1.1.1.27 / L-Lactate Dehydrogenase; VAP-cyclo protocol
  •  go-up   go-down


42. Sase T, Wada H, Yamaguchi M, Ogawa S, Kamikura Y, Nishikawa M, Kaneko T, Abe Y, Nishioka J, Nobori T, Shiku H: Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost; 2005 Jan;93(1):153-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haemostatic abnormalities and thrombotic disorders in malignant lymphoma.
  • We examined haemostatic abnormalities and thrombotic disorders in 217 patients with malignant lymphoma.
  • Plasma levels of fibrinogen and D-dimer were significantly higher in patients with malignant lymphoma than in healthy subjects.
  • The incidence of severe complications, such as disseminated intravascular coagulation (DIC) and interstitial pneumonia (IP), differed with each clinical stage or histological type, but they occurred frequently in stage IV or natural killer (NK) cell lymphoma.
  • Plasma levels of fibrinogen degradation products (FDP) and D-dimer, leukocyte tissue factor (TF) mRNA and plasma TF antigen were significantly higher in stage IV than in stage I, II or III.
  • Plasma levels of FDP, D-dimer, and leukocyte TF mRNA in NK cell lymphoma were markedly higher than in other types of lymphoma.
  • Immunohistochemical staining of NK cell lymphoma revealed that granulocyte macrophage colony-stimulating factor was positive in tumour cells, whereas von Willebrand factor and TF were positive in vascular endothelial cells of surrounding tissue.
  • Our results suggested that patients with stage IV disease and NK cell lymphoma were in abnormal thrombotic and haemostatic state, and may frequently develop DIC and IP.
  • One of the mechanisms of DIC and IP may involve elevated cytokine production by lymphoma cells, which can stimulate the expression of TF in blood cells or surrounding tissue.
  • [MeSH-major] Hemostasis. Lymphoma / complications. Thrombosis / etiology

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thromb Haemost. 2005 Jan;93(1):1-2 [15630482.001]
  • (PMID = 15630506.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


43. Lin XG, Huang KH, Xie DR, Liu TH: [Prognostic factor analysis of 116 cases of primary gastrointestinal non-Hodgkin's lymphoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb;28(2):243-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factor analysis of 116 cases of primary gastrointestinal non-Hodgkin's lymphoma].
  • OBJECTIVE: To investigate the factors that affect the prognosis of primary gastrointestinal non-Hodgkin's lymphoma (PGI-NHL).
  • Univariate analysis revealed that the factors affecting the prognosis of the patients included the presence of B symptom, tumor size, clinical stage, pathological type, depth of invasion, and treatment methods.
  • The patients with B symptom, tumor size no less than 10 cm, advanced clinical stage (stages III(E) and IV(E)), T-cell type, and invasion beyond the serosa who received only surgical management had poorer prognosis than those free of B symptom with tumor size <10 cm, early clinical stage (stages I(E) and II(E)), B-cell type, and submucosal or serosal invasion managed with chemotherapy alone or in combination with surgery.
  • Multivariate analysis showed that B symptom, tumor size no less than 10 cm, advanced clinical stage (stages III(E) and IV(E)), T-cell type, invasion beyond the serosa, and surgery alone were independently associated with poor prognosis.
  • CONCLUSION: The tumor size, clinical stage, pathological type, treatment methods are the independent factors affecting the prognosis of patients with PGI-NHL.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250053.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


44. Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, Coiffier B, Bosly A, Diviné M, Brice P: Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer; 2010 Feb 1;116(3):631-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.
  • BACKGROUND: Nodular, lymphocyte-predominant Hodgkin lymphoma (NLPHL) represents a rare entity.
  • To determine the histologic transformation (HT) rate to diffuse large B-cell lymphoma (DLBCL) and long-term outcomes, 164 patients were selected after histologic review.
  • The median patient age was 30 years (range, 6-69 years), 80% of patients were men, 83% had Ann Arbor stage I/II disease, 65% had supradiaphragmatic-disease; 27% received radiotherapy, 9% received chemotherapy, 29% received combined-modality therapy, and 35% were followed with a watch-and-wait strategy.
  • The 19 patients who had HT were treated with curative intent: Nine patients received high-dose therapy with subsequent autologous stem cell transplantation (ASCT), and 10 patients received different chemotherapy regimens.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic. Child. Female. Humans. Longitudinal Studies. Lymphoma / classification. Lymphoma / pathology. Male. Middle Aged. Recurrence. Time Factors


45. Tsang RW, Gospodarowicz MK: Low-grade non-hodgkin lymphomas. Semin Radiat Oncol; 2007 Jul;17(3):198-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade non-hodgkin lymphomas.
  • The most common low-grade non-Hodgkin lymphomas are of B-cell origin.
  • Moderate doses (30-35 Gy) for these stage I and II low-grade lymphomas result in long-term local control and possible cure.
  • For follicular lymphoma, this occurs in approximately 50% of patients after 15 years and for nongastric MALT lymphoma 30% to 40% after 10 years.
  • Patients with stage III and IV low-grade lymphoma and local symptoms are often successfully palliated with a low dose regimen of 2 x 2 Gy (total dose 4 Gy).
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Helicobacter Infections / radiotherapy. Helicobacter pylori / radiation effects. Humans. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, Follicular / radiotherapy. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Palliative Care. Prognosis. Radiotherapy Dosage. Stomach Neoplasms / microbiology. Stomach Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591567.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


46. Schneider T, Molnár Z, Deák B, Várady E, Tóth E, Csomor J, Matolcsy A, Lovey J, Lengyel Z, Petri K, Gaudi I, Rosta A: [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma]. Orv Hetil; 2009 Nov 1;150(44):2019-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
  • [Transliterated title] Diffúz nagy B-sejtes lymphomák immunokemoterápiás kezelésével elért eredményeink.
  • Treatment with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been considered as the standard therapy for diffuse large B-cell lymphoma (DLBCL) for more than 20 years.
  • The eligibility criteria included advanced stage (clinical stages III-IV), or large tumour size (>7 cm) and/or symptom B or extranodal manifestation in the case of clinical stages I-II.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / immunology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861288.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


47. Di Lorenzo G, Di Trolio R, Delfino M, De Placido S: Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. Br J Dermatol; 2005 Jul;153(1):183-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegylated liposomal doxorubicin in stage IVB mycosis fungoides.
  • BACKGROUND: Previous studies have shown that pegylated liposomal doxorubicin (LD) is effective in the treatment of relapsing or recalcitrant cutaneous T-cell lymphoma.
  • OBJECTIVES: To evaluate the activity and toxicity of LD in patients with stage IVB mycosis fungoides (MF).
  • CONCLUSIONS: This study demonstrates that LD is beneficial in terms of activity and toxicity in stage IVB MF.

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029347.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


48. Machii T, Chou T, Suzuki M, Ohe Y, Katagiri S, Kitano EK, Kitano K, Fujiyama Y, Izumi T, Shimazaki C, Nanba K, Ohashi Y, Kitani T, Cladribine Study Group: Phase II clinical study of cladribine in the treatment of hairy cell leukemia. Int J Hematol; 2005 Oct;82(3):230-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical study of cladribine in the treatment of hairy cell leukemia.
  • We conducted a phase II clinical study to evaluate the therapeutic efficacy of cladribine (2-chlorodeoxyadenosine [2-CdA]) in the treatment of Japanese patients with hairy cell leukemia (HCL).
  • During the early stage after administration, further hematologic impairment occurred, but subsequent peripheral blood counts gradually recovered as 2-CdA treatment showed antitumor activity.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cladribine / administration & dosage. Leukemia, Hairy Cell / drug therapy

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1997 May;11(5):629-32 [9180283.001]
  • [Cites] Leuk Lymphoma. 1994;14 Suppl 1:121-5 [7820043.001]
  • [Cites] Rinsho Ketsueki. 1988 Nov;29(11):2029-36 [3070073.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1138-42 [9060556.001]
  • [Cites] Blood. 1982 Sep;60(3):571-7 [7104487.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:24-7 [1349662.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1111-20 [1371410.001]
  • [Cites] Jpn J Clin Oncol. 1993 Aug;23(4):250-7 [8411739.001]
  • [Cites] Leuk Res. 1980;4(6):547-59 [7206776.001]
  • [Cites] Leukemia. 1993 Feb;7(2):181-6 [8426471.001]
  • [Cites] N Engl J Med. 1990 Apr 19;322(16):1117-21 [1969613.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):512-7 [12841391.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1918-26 [9731048.001]
  • [Cites] Lancet. 1992 Oct 17;340(8825):952-6 [1357355.001]
  • [Cites] Ann Hematol. 1999 Mar;78(3):139-44 [10211756.001]
  • [Cites] Nihon Ketsueki Gakkai Zasshi. 1989 Dec;52(8):1279-86 [2698043.001]
  • [Cites] Jpn J Med. 1990 Jul-Aug;29(4):379-83 [2273621.001]
  • [Cites] Semin Oncol. 1984 Dec;11(4):362-9 [6594759.001]
  • [Cites] Leuk Lymphoma. 1993;11 Suppl 2:109-14 [7907251.001]
  • [Cites] Jpn J Clin Oncol. 1997 Jun;27(3):146-53 [9255268.001]
  • [Cites] Blood. 1992 Feb 15;79(4):888-94 [1346578.001]
  • [Cites] Int J Hematol. 2004 Oct;80(3):267-77 [15540903.001]
  • [Cites] Mol Pharmacol. 2004 Jan;65(1):227-34 [14722255.001]
  • [Cites] Leukemia. 1995 Jan;9(1):25-9 [7845025.001]
  • [Cites] Blood. 1990 Jul 1;76(1):157-62 [2364167.001]
  • [Cites] Jpn J Clin Oncol. 1983 Sep;13(3):497-509 [6645081.001]
  • (PMID = 16207596.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


49. Pulsoni A, Starza ID, Frattarelli N, Ghia E, Carlotti E, Cavalieri E, Matturro A, Tempera S, Rambaldi A, Foà R: Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy. Br J Haematol; 2007 May;137(3):216-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy.
  • Stage I/IIA follicular lymphoma (FL) is considered a localised disease that can be adequately treated with radiotherapy alone.
  • Despite the limited stage, Bcl-2/IgH+ cells were found at diagnosis in PB and/or BM of 16 patients (66.6%).
  • Quantitative PCR demonstrated the feasibility of clearing PB and BM Bcl-2+ cells after local irradiation of the primary site of the disease only when the basal number of lymphoma cells was <1:100 000.
  • Lymphoma cells can reversibly spread from the affected lymph node to PB and BM and, in a proportion of cases, durably disappear after irradiation.
  • The possibility of a persistent lymphoma cell clearance is proportional to the amount of cells detected at presentation by quantitative PCR.
  • [MeSH-major] Bone Marrow / pathology. Genes, bcl-2 / genetics. Lymphoma, Follicular / radiotherapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408460.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


50. Avilés A, Neri N, Nambo MJ, Huerta-Guzman J, Cleto S: Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma. Med Oncol; 2006;23(2):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma.
  • BACKGROUND AND OBJECTIVES: Treatment of high-grade MALT (mucosa-associated lymphoid tissue) gastric lymphoma remains uncertain.
  • To assess efficacy and toxicity of the most common therapies--surgery followed by chemotherapy or chemotherapy alone--we began a controlled clinical trial in patients in early stage (I and II 1).
  • CONCLUSIONS: The use of surgery and chemotherapy did not improve outcome in patients with early-stage high-grade gastric MALT lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / therapy

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2002 May;55(5):346-51 [11986338.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3874-83 [11559725.001]
  • [Cites] Surgery. 1997 May;121(5):501-5 [9142147.001]
  • [Cites] Am J Surg. 2000 Mar;179(3):216-22 [10827324.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):12-8 [14679113.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Haematologica. 2000 Apr;85(4):372-80 [10756362.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1466-74 [9136823.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] J Clin Pathol. 2000 Mar;53(3):187-90 [10823136.001]
  • [Cites] Gut. 1992 Oct;33(10):1307-11 [1446850.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):1020-9 [7927306.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1641-9 [11117785.001]
  • [Cites] Gastroenterology. 1991 Nov;101(5):1159-70 [1936785.001]
  • [Cites] J Surg Oncol. 2003 Jun;83(2):106-11 [12772204.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Ann Oncol. 1995 Apr;6(4):355-62 [7619750.001]
  • [Cites] Histopathology. 2002 Feb;40(2):117-26 [11952855.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • [Cites] Gut. 2001 Mar;48(3):297-303 [11171816.001]
  • (PMID = 16720930.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP-B protocol
  •  go-up   go-down


51. Kitszel A, Krawczuk-Rybak M: Are elevated serum levels of IGFBP-2 after intensive chemotherapy of childhood acute lymphoblastic leukemia a risk factor of relapse? Adv Med Sci; 2007;52:147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the serum levels IGF-I, IGF-II, IGFBP-3 and IGFBP-2 (expressed in SDS) in a subgroup with relapse (A) and in a subgroup without relapse (B) at diagnosis (1), after induction of remission (2) and after intensive chemotherapy (3).
  • RESULTS: It was found that in subgroup A, the values of IGFBP-2 remained high at each stage of the investigation: 3.92 +/- 2.50 (1) 3.68 +/- 0.99 (2) 3.52 +/- 1.26 (3), whereas in the subgroup B they underwent a significant reduction from 3.87 +/- 1.86 (1) 3.45 +/- 1.25 (2) 2.15 +/- 1.84 (3), p = 0.02.
  • In comparison to a control group, the correlations between IGF-I and IGFBP-3, and IGF-1 and IGFBP-2 were disturbed for the whole group of children at each stage of the investigation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gene Expression Regulation, Leukemic. Insulin-Like Growth Factor Binding Protein 2 / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


52. Isobe K, Kagami Y, Higuchi K, Kodaira T, Hasegawa M, Shikama N, Nakazawa M, Fukuda I, Nihei K, Ito K, Teshima T, Matsuno Y, Oguchi M, Japan Radiation Oncology Group: A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas: a preliminary report from the Japan Radiation Oncology Group (JAROG). Int J Radiat Oncol Biol Phys; 2007 Nov 15;69(4):1181-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas: a preliminary report from the Japan Radiation Oncology Group (JAROG).
  • PURPOSE: The aim of this study was to evaluate the efficacy and toxicity of moderate dose radiation therapy (RT) for mucosa-associated lymphoid tissue (MALT) lymphoma in a prospective multicenter phase II trial.
  • METHODS AND MATERIALS: The subjects in this study were 37 patients with MALT lymphoma between April 2002 and November 2004.
  • CONCLUSIONS: This prospective phase II study demonstrated that moderate dose RT was highly effective in achieving local control with acceptable morbidity in 37 patients with MALT lymphoma.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601683.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Aktaş S, Kargi A, Olgun N, Diniz G, Erbay A, Vergin C: Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein-Barr Virus positive and negative pediatric non-Hodgkin's lymphoma. Pathol Oncol Res; 2009 Sep;15(3):345-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein-Barr Virus positive and negative pediatric non-Hodgkin's lymphoma.
  • Apoptosis-related proteins and proliferation activity and their relationship with Epstein-Barr Virus (EBV) are contemporary issues in pediatric non-Hodgkin's lymphoma (pNHL).
  • Seven cases were stage I/II and 63 cases were stage III/IV.
  • [MeSH-major] Apoptosis / physiology. Cell Proliferation. Epstein-Barr Virus Infections / metabolism. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / virology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1991;27(12):1643-5 [1782076.001]
  • [Cites] Arch Pathol Lab Med. 2002 Mar;126(3):331-5 [11860309.001]
  • [Cites] Pediatr Pathol Mol Med. 2002 Nov-Dec;21(6):525-30 [12537769.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1569-77 [15370208.001]
  • [Cites] J Pathol. 2003 Jun;200(2):240-8 [12754745.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):527-35 [11485911.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2249-55 [12613509.001]
  • [Cites] Leuk Lymphoma. 2000 Oct;39(3-4):329-37 [11342313.001]
  • [Cites] Am J Hematol. 2001 Jun;67(2):84-92 [11343379.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):874-82 [16784988.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):501-10 [14742256.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1474-82 [15746049.001]
  • [Cites] Blood. 2004 Jan 15;103(2):695-7 [12969962.001]
  • [Cites] Lymphat Res Biol. 2007;5(3):175-82 [18035936.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):384-92 [15023043.001]
  • [Cites] Exp Oncol. 2005 Jun;27(2):96-101 [15995625.001]
  • [Cites] Int J Hematol. 2004 Apr;79(3):260-5 [15168595.001]
  • [Cites] Pathol Res Pract. 2002;198(5):327-32 [12092768.001]
  • [Cites] J Clin Pathol. 1992 Aug;45(8):660-3 [1401173.001]
  • [Cites] Hematol J. 2000;1(1):53-66 [11920170.001]
  • [Cites] Pediatr Transplant. 2003 Feb;7(1):46-52 [12581328.001]
  • [Cites] Oncogene. 2008 Jan 17;27(4):421-33 [17653091.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):115-9 [15236276.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1796-805 [9823956.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):771-6 [12118116.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3715-21 [17682125.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3361-4 [15150084.001]
  • [Cites] Pediatr Hematol Oncol. 1996 Mar-Apr;13(2):123-34 [8721026.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):696-703 [9973220.001]
  • [Cites] Oncologist. 2003;8(1):83-98 [12604735.001]
  • [Cites] Haematologica. 1998 Mar;83(3):209-16 [9573674.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2860-6 [10537354.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):158-65 [10697273.001]
  • (PMID = 19048401.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


54. Bariakh EA, Kravchenko SK, Kremenetskaia AM, Zvonkov EE, Obukhova TN, Magomedova AU, Vorob'ev AI: [Clinical and epidemiological features of Burkitt's lymphoma]. Ter Arkh; 2009;81(7):47-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and epidemiological features of Burkitt's lymphoma].
  • AIM: To characterize clinical and epidemiological features of adult Berkitt's lymphoma (BL).
  • RESULTS: Stage I BL (by S.B.
  • Murphy) was diagnosed in 5 patients, stage II--in 9, stage III--in 25, IV--in 14 patients, B-cell acute lymphoblastic leukemia (ALL) (L3)--in 19 patients.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708573.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


55. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS: Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol; 2010 Sep 20;28(27):4170-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
  • PURPOSE: The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
  • Variables including age, sex, Ann Arbor disease stage, bulky disease status, standardized uptake values (SUVs) on positron emission tomography (PET), International Prognostic Index (IPI), and Ki67 staining (proliferation).
  • RESULTS: Of 469 patients, 190 (40.5%) had stage I or II disease and 279 (59.5%) had stage III or IV disease, 327 (70%) had at least six cycles of R-CHOP, and 142 (30.2%) had involved-field RT (dose, 30 to 39.6 Gy) after complete response to chemotherapy.
  • Matched-pair analyses of patients who received six to eight cycles of R-CHOP with stage I or II disease (44 pairs) and all stages (74 pairs) indicated that RT improved OS (hazard ratio [HR], 0.52 and 0.29, respectively) and PFS (HR, 0.45 and 0.24, respectively) compared with no RT.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Prednisone / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cell Proliferation. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Matched-Pair Analysis. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Rituximab. Survival Analysis. Texas. Time Factors. Treatment Outcome. Young Adult


56. Sakai C, Murotani N: [Adult T-cell leukemia/lymphoma in a patient on hemodialysis-resistance to CHOP, but unexpected effect and remission achieved by sobuzoxane alone]. Gan To Kagaku Ryoho; 2010 Feb;37(2):347-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult T-cell leukemia/lymphoma in a patient on hemodialysis-resistance to CHOP, but unexpected effect and remission achieved by sobuzoxane alone].
  • The pathological diagnosis was peripheral T-cell lymphoma, CD4(+).
  • He was clinically diagnosed as having an adult T-cell leukemia/lymphoma, lymphoma type, and clinical stage II.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Leukemia-Lymphoma, Adult T-Cell / complications. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Piperazines / therapeutic use. Renal Dialysis. Renal Insufficiency / complications

  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154500.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Piperazines; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; R1308VH37P / sobuzoxane; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


57. Jiang XF, Yang KX, Peng ZL, Xu L, Huang Q, Li Q: [Clinicopathologic and immunohistochemical study of primary non-Hodgkin lymphoma of the female genital system]. Zhonghua Fu Chan Ke Za Zhi; 2007 Apr;42(4):222-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic and immunohistochemical study of primary non-Hodgkin lymphoma of the female genital system].
  • OBJECTIVE: To investigate the clinicopathology and immunophenotype of primary non-Hodgkin lymphoma (NHL) of the female genital system, and to analyze the prognosis of such tumors.
  • (1) Primary lesions: there were 24 cases of lymphoma originating in the ovary, 3 cases in the endometrium, 10 cases in the cervix, 2 cases in the vagina and 4 cases in the vulva. (2) Staging: 12 cases (28%) were in stage I, 9 cases (21%) in stage II, and 22 cases (51%) in stage III. (3) Histological classification: 37 cases (86%) were diffuse large B cell lymphoma (DLBCL), 3 cases were Burkitt lymphoma and the remaining 3 cases were unspecified peripheral T-cell lymphoma according to biopsy, immunophenotype analysis, in-situ-hybridization technique and IgH gene rearrangement detection. (4) Prognosis analysis: increase in the level of lactic acid dehydrogenase, stage III, DLBCL and single operation suggest poor prognosis.
  • [MeSH-major] Genital Neoplasms, Female / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers. Female. Humans. Immunohistochemistry. Immunophenotyping. L-Lactate Dehydrogenase. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Polymerase Chain Reaction. Prognosis. Retrospective Studies. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631759.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


58. Yu JI, Nam H, Ahn YC, Kim WS, Park K, Kim SJ: Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma. Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):507-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma.
  • PURPOSE: To report treatment outcomes after combined-modality therapy in patients with Stage I/II head-and-neck (HN) diffuse large B cell lymphoma (DLBL).
  • CONCLUSION: This study demonstrated that patients with Stage I/II HN DLBL did not need whole-neck irradiation.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20056353.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


59. Hekimgil M, Cağirgan S, Pehlivan M, Doğanavşargil B, Tombuloğlu M, Soydan S: Immunohistochemical detection of CD 95 (Fas) & Fas ligand (Fas-L) in plasma cells of multiple myeloma and its correlation with survival. Leuk Lymphoma; 2006 Feb;47(2):271-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple myeloma (MM) is a malignant disease resulting from an uncontrolled proliferation of a neoplastic plasma cell clone in the bone marrow, which might also be induced by the loss of control on apoptosis.
  • In the present study, immunostaining was performed on the initial diagnostic bone marrow biopsies of 36 MM patients (1 stage I, 5 stage II, 30 stage III), to evaluate the distribution of Fas receptor and Fas-L on malignant plasma cells.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321857.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Tumor Necrosis Factors
  •  go-up   go-down


60. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA: Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J; 2005 Sep-Oct;11(5):425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
  • This study assessed efficacy, optimal dosage and timing, and toxicity of involved-field radiotherapy used in conjunction with high-dose chemotherapy and stem cell transplantation for patients with refractory/relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS AND MATERIALS: 306 patients with refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma were analyzed.
  • Forty-one patients underwent involved-field radiotherapy in conjunction with high-dose chemotherapy and bone marrow or peripheral stem cell transplantation.
  • Thirty-three patients received involved-field radiotherapy prior to stem cell transplantation directed at symptomatic and/or bulky sites; eight patients received involved-field radiotherapy after stem cell transplantation directed at sites of persistent disease.
  • The other 265 patients with refractory/relapsed non-Hodgkin's lymphoma and Hodgkin's disease received high-dose chemotherapy/stem cell transplantation, but not involved-field radiotherapy.
  • Data were analyzed using Cox proportional hazards regression to determine the risk of death among patients treated with stem cell transplantation compared with that among patients treated with stem cell transplantation and involved-field radiotherapy.
  • Multivariate analysis found that patients who did not receive involved-field radiotherapy were 2.09 times more likely to die during the follow-up period than patients who received involved-field radiotherapy (P = 0.066; adjusted for age, stem cell transplantation type, stage I/II vs stage III/IV, refractory vs relapsed, and Hodgkin's disease vs non-Hodgkin's lymphoma).
  • When patients were treated with involved-field radiotherapy prior to stem cell transplantation, 27 (79.4%) of the 34 patients achieved local control; when involved-field radiotherapy followed stem cell transplantation, 6 (85.7%) of the 7 patients experienced local control.
  • Timing of involved-field radiotherapy prior to or following stem cell transplantation did not affect patient survival.
  • CONCLUSIONS: Although of borderline significance in this small sample, results of this study suggest that patients who receive involved-field radiotherapy in conjunction with stem cell transplantation may have increased survival when compared with patients who do not receive involved-field radiotherapy.
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259874.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ: Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma; 2009 Dec;9(6):412-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
  • INTRODUCTION: Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies.
  • PATIENTS AND METHODS: A multicenter, open-label phase IIb trial evaluated the activity and safety of vorinostat 400 mg orally daily in patients with > or = stage IB, persistent, progressive, or treatment-refractory mycosis fungoides or Sézary syndrome CTCL subtypes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Histone Deacetylase Inhibitors / therapeutic use. Hydroxamic Acids / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951879.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  •  go-up   go-down


62. Kim JH, Lee JH, Lee J, Oh SO, Chang DK, Rhee PL, Kim JJ, Rhee JC, Lee J, Kim WS, Ko YH: Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings. Endoscopy; 2007 Feb;39(2):156-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings.
  • BACKGROUND AND STUDY AIMS: Primary NK-/T-cell lymphoma of the gastrointestinal tract is a very rare disease with a poor prognosis.
  • The aim of this study was to determine the clinical and endoscopic characteristics of patients with primary gastrointestinal NK-/T-cell lymphoma.
  • PATIENTS AND METHODS: The clinical features of 14 patients with primary gastrointestinal NK-/T-cell lymphoma and the endoscopic findings in 11 of these patients were reviewed.
  • RESULTS: The initial presenting symptoms of primary gastrointestinal NK-/T-cell lymphoma were gastrointestinal bleeding (n = 6, 42%), abdominal pain (n = 4, 29%), and epigastric soreness (n = 4, 29%).
  • The disease was at an advanced stage at the time of diagnosis: stage II in 5 patients (36%); stage III in 4 (28%); and stage IV in 5 (36%).
  • CONCLUSIONS: Primary gastrointestinal NK-/T-cell lymphoma was endoscopically characterized by superficial/erosive, ulcerative, or ulceroinfiltrative lesions without fungating mass.
  • [MeSH-major] Endoscopy, Gastrointestinal. Gastrointestinal Neoplasms / pathology. Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657701.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Hall GW, Katzilakis N, Pinkerton CR, Nicolin G, Ashley S, McCarthy K, Daw S, Hewitt M, Wallace WH, Shankar A: Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report. Br J Haematol; 2007 Sep;138(6):761-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.
  • This report describes the clinical outcomes and follow-up records of 42 children with nodular lymphocyte predominant Hodgkin lymphoma (LPHL) treated on United Kingdom Children's Cancer Study Group (UKCCSG) HD1 (1982-1992) and HD2 protocols (1992-2000).
  • In both trials, only patients with stage IA disease had the option of being treated with either involved field radiation alone or combination chemotherapy consisting of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP).
  • Thirty-five patients (83%) presented with early stage disease (Stages I & II).
  • In conclusion, children with low-stage LPHL treated between 1982 and 2000 according to the UK strategy for classical Hodgkin lymphoma (HL) had an excellent prognosis.
  • There have been no second malignancies or transformations to B-cell non-Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760808.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 35S93Y190K / Procarbazine; 5V9KLZ54CY / Vinblastine; VB0R961HZT / Prednisone; CHIVPP protocol
  •  go-up   go-down


64. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD: The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood; 2010 Jan 14;115(2):289-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation.
  • Previous studies of follicular lymphoma (FL) patients treated heterogeneously have suggested that decreased numbers of regulatory T cells correlates with improved survival.
  • We studied advanced-stage FL patients from a single institution phase 2 trial.
  • Both cell content and cell distribution were evaluated.
  • Cell content did not impact survival, while immunoarchitectural patterns of CD4/CD8 were significant for progression-free survival (PFS; P = .056), CD25 for both PFS and OS (P = .002 and P = .024, respectively), and FOXP3(+) predicted PFS, OS, and RT (P = .001, P < .001 and p = .002, respectively).
  • We conclude that FOXP3(+) cell distribution significantly predicts survival and RT in FL.
  • [MeSH-major] Cell Transformation, Neoplastic / immunology. Forkhead Transcription Factors / immunology. Lymphoma, Follicular / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Antigens, CD. CD4-CD8 Ratio. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Survival Rate

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19901260.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / STP-53912
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


65. Hainsworth JD, Flinn IW, Spigel DR, Clark BL, Griner PL, Vazquez ER, Doss HH, Shipley D, Franco LA, Burris HA 3rd, Greco FA, Sarah Cannon Oncology Research Consortium: Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma Leuk; 2010 Feb;10(1):44-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
  • INTRODUCTION: Patients with diffuse large B-cell lymphoma (DLBCL) who are very elderly or have poor performance status are difficult to treat with a full course of R-CHOP (rituximab plus cyclophosphamide/doxorubicin/vincristine/ prednisone) therapy.
  • In this phase II trial, we treated this group of patients with a novel regimen containing 3 courses of rituximab/chemotherapy followed by maintenance rituximab.
  • PATIENTS AND METHODS: Patients with newly diagnosed stage II-IV DLBCL were eligible if they were considered poor candidates for 6-8 cycles of R-CHOP therapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223728.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


66. Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, Kim TY, Kim CW, Heo DS, Bang YJ, Chang KH, Kim NK: Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood; 2005 Dec 1;106(12):3785-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type.
  • This study was launched to determine the prognostic significance of local tumor invasiveness (LTI) in 114 patients diagnosed with stage I(E)/II(E) extranodal natural killer (NK)/T-cell lymphoma, nasal type (NTCL).
  • Complete remission (CR), overall survival (OS), and disease-free survival (DFS) were compared between each group according to LTI, Ann Arbor stage, and International Prognostic Index (IPI).
  • LTI is the most important prognostic factor in predicting low probability of CR and reduced OS and DFS in nasal stage I(E)/II(E) NTCL.
  • [MeSH-major] Lymphoma, T-Cell / mortality. Neoplasm Invasiveness. Neoplasm Staging. Nose Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109779.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Han S, Chen Y, Ge X, Zhang M, Wang J, Zhao Q, He J, Wang Z: Epidemiology and cost analysis for patients with oral cancer in a university hospital in China. BMC Public Health; 2010;10:196
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epidemical characteristics are as follows: female/male 176/280; squamous cell carcinoma (SCC)/adenocarcinoma/sarcoma/lymphoma/other types 246/127/40/27/16; stage I/II/III/IV 90/148/103/115; smoker/non-smoker 136/320; rural/urban patients 82/374.
  • The CPP and MHD of patients in late clinical stage were higher than that of patient in early stage.
  • Lack of medicare, smoking habit, late clinical stage and SCC are the high economic factors for patient medical cost.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Maxillofac Surg. 2003 Jul;61(7):751-8 [12856245.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Feb;129(2):219-28 [12578453.001]
  • [Cites] J Am Dent Assoc. 1972 Sep;85(3):637-40 [4505593.001]
  • [Cites] N Engl J Med. 1982 May 13;306(19):1151-5 [7040958.001]
  • [Cites] Oper Dent. 1989 Summer;14(3):114-20 [2637996.001]
  • [Cites] J Clin Anesth. 1994 Sep-Oct;6(5):357-63 [7986506.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):745-53 [9469366.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1626-36 [9811312.001]
  • [Cites] Support Care Cancer. 2005 Jan;13(1):32-41 [15549427.001]
  • [Cites] Oncologist. 2006 Jun;11(6):590-601 [16794238.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jul;102(1):67-76 [16831675.001]
  • [Cites] Mayo Clin Proc. 2007 Jul;82(7):878-87 [17605971.001]
  • [Cites] Head Neck. 2008 Feb;30(2):178-86 [17694558.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2008 Apr;16(2):113-6 [18327029.001]
  • [Cites] J Can Dent Assoc. 2008 Apr;74(3):269-72 [18387267.001]
  • [Cites] J Can Dent Assoc. 2008 Apr;74(3):245 [18401902.001]
  • [Cites] Oral Dis. 2008 May;14(4):314-9 [18449960.001]
  • [Cites] J Oral Maxillofac Surg. 2008 Aug;66(8):1570-9 [18634942.001]
  • [Cites] Stomatologiia (Mosk). 2008;87(6):21-3 [19156101.001]
  • [Cites] Oral Oncol. 2009 Nov;45(11):958-62 [19502101.001]
  • [Cites] Br Dent J. 2000 Mar 11;188(5):262-5 [10758688.001]
  • [Cites] J Dent Educ. 2001 Apr;65(4):328-39 [11336118.001]
  • [Cites] Med Pediatr Oncol. 2002 Sep;39(3):149-55 [12210442.001]
  • [Cites] BMC Public Health. 2002 Jul 19;2:12 [12133170.001]
  • [Cites] J Can Dent Assoc. 2004 May;70(5):302-4 [15132812.001]
  • (PMID = 20398380.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2864212
  •  go-up   go-down


68. Diepstra A, van Imhoff GW, Schaapveld M, Karim-Kos H, van den Berg A, Vellenga E, Poppema S: Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol; 2009 Aug 10;27(23):3815-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients.
  • PURPOSE: In classical Hodgkin's lymphoma (cHL), the impact of tumor cell Epstein-Barr virus (EBV) status on clinical outcome is controversial.
  • Tumor cell EBV status was positive in 34%, and the median follow-up time was 7.1 years.
  • Patients' median age at diagnosis was 35 years (range, 7 to 91 years), and 63% had Ann Arbor stage I or II, 24% had stage III, and 12% had stage IV disease.
  • After adjusting for histology, HLA class II expression by tumor cells, stage, presence of extranodal localizations and treatment, and the effect of positive EBV tumor status remained significant in FFS multivariate analysis (hazard ratio, 3.11; 95% CI, 1.28 to 7.53; P = .01).
  • CONCLUSION: This study indicates that treatment failure in older adult patients with cHL is associated with positive tumor cell EBV status.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470931.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


69. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE: Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol; 2009 Aug 10;27(23):3808-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
  • PATIENTS AND METHODS: Previously untreated patients with asymptomatic Rai stage 0 to II CLL were eligible for participation.
  • A phase II trial to evaluate efficacy using 2,000 mg twice a day began in November 2007.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Catechin / analogs & derivatives. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2000 Mar 15;279(2):164-9 [10706785.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3807-17 [18599795.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):844-50 [11259102.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13322-30 [11278274.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:25-54 [11807163.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):381-5 [11809684.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):854-61 [11843819.001]
  • [Cites] Arch Pharm Res. 2002 Oct;25(5):561-71 [12433185.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):824-30 [12591733.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1466-71 [12697868.001]
  • [Cites] Curr Treat Options Oncol. 2003 Jun;4(3):211-8 [12718798.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3312-9 [12960117.001]
  • [Cites] Biochem Pharmacol. 2003 Nov 1;66(9):1769-78 [14563487.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7563-70 [14633667.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8118-21 [14678963.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1202-10 [14576043.001]
  • [Cites] Toxicol In Vitro. 2004 Oct;18(5):555-61 [15251172.001]
  • [Cites] Blood. 2004 Aug 1;104(3):788-94 [14996703.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1567-74 [15090467.001]
  • [Cites] Hematol Oncol. 1988 Jan-Mar;6(1):7-12 [3277904.001]
  • [Cites] Br J Haematol. 1989 Jun;72(2):141-9 [2757960.001]
  • [Cites] Mayo Clin Proc. 1994 Apr;69(4):323-8 [8170175.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):393-9 [7655336.001]
  • [Cites] Leukemia. 1996 Mar;10(3):456-9 [8642861.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):134-5 [9296488.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 17;89(24):1881-6 [9414176.001]
  • [Cites] Leuk Lymphoma. 1997 Nov;27(5-6):523-32 [9477135.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1506-14 [9593789.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 19;249(2):391-6 [9712707.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2059-64 [15781612.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4627-33 [15958649.001]
  • [Cites] Leuk Res. 2006 Jun;30(6):707-12 [16325256.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1227-38 [16731755.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1419-21 [16645636.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):435-47 [16983131.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2804-10 [16809610.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):223S-228S [17182830.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2144-50 [17404098.001]
  • [Cites] J Cell Physiol. 2007 Oct;213(1):252-60 [17477351.001]
  • [Cites] Life Sci. 2007 Jul 26;81(7):519-33 [17655876.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):395-402 [17686632.001]
  • [Cites] Blood. 2008 Jan 15;111(2):846-55 [17928528.001]
  • [Cites] J Cell Biochem. 2008 Feb 1;103(2):509-19 [17570133.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):537-46 [18275431.001]
  • [Cites] Antioxid Redox Signal. 2008 Mar;10(3):475-510 [18154485.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1923-30 [18577710.001]
  • [Cites] Cancer Lett. 2008 Oct 8;269(2):269-80 [18501505.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1830-8 [11251015.001]
  • (PMID = 19470922.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / R01 CA136591; United States / NCI NIH HHS / CA / CA113408; United States / NCI NIH HHS / CA / CA6912
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Tea; 0 / polyphenon E; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  • [Other-IDs] NLM/ PMC2727287
  •  go-up   go-down


70. Vural F, Akad Soyer N, Özen P, Dönmez A, Ocakçı S, Saydam G, Çağırgan S, Tombuloğlu M: Non-Hodgkin's lymphoma with bone involvement: a single center experience with 18 patients. Turk J Haematol; 2010 Mar 5;27(1):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma with bone involvement: a single center experience with 18 patients.
  • [Transliterated title] Kemik tutulumlu Hodgkin dışı lenfoma: Onsekiz hasta ile tek merkez deneyimi.
  • OBJECTIVE: Non-Hodgkin's lymphoma (NHL) of bone is a rare entity.
  • The most common histological subtype is diffuse large B cell lymphoma (DLBCL).
  • Other histological subtypes were anaplastic large cell lymphoma (11.1%), Burkitt-like lymphoma (5.6%) and marginal zone lymphoma (5.6%).
  • According to Ann Arbor staging system, 44.4% of patients were Stage I, 11.1% were Stage II and 44.4% were Stage IV.
  • CONCLUSION: The treatment of bone lymphoma can be planned according to the stage and location of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265795.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


71. Avenia N, Sanguinetti A, Cirocchi R, Bistoni G, Trastulli S, D'Ajello F, Barberini F, Cavallaro G, Rulli A, Sidoni A, Noya G, De Toma G, Sciannameo F: Primary breast lymphomas: a multicentric experience. World J Surg Oncol; 2010;8:53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The Primary Breast Lymphomas (PBL) represent 0,38-0,70% of all non-Hodgkin lymphomas (NHL), 1,7-2,2% of all extranodal NHL and only 0,04-0,5% of all breast cancer.
  • Most frequent PBLs are the diffuse large B cell lymphomas; in any case-reports MALT lymphomas lack or are a rare occurrence.
  • Pathologic examination revealed 16 diffuse large B cell lymphomas and 7 MALT lymphomas.
  • RESULTS: Seven patients in the mastectomy group had a recurrence (50%), and all of them with diffuse large B cell lymphomas at stage II.
  • For stage IE DFS and OS at 5 and 10 years were 100%.
  • For stage II DFS at 10 years was 62.5% and 56.2% respectively; OS at 5 and 10 years was 75% and 62.5% respectively.
  • For diffuse large B cell lymphomas DFS at 5 and 10 years was 62.5% and 56.2% respectively; OS at 5 and 10 years was 75% and 62,5% respectively.
  • MALT PBLs have a definitely better prognosis compared to large B cell lymphomas.
  • Axillary dissection must always be performed for staging purposes, so avoiding the risk of under-staging II or IE, due to the possibility of clinically silent axillary node involvement.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1999 Dec;123(12):1208-18 [10583925.001]
  • [Cites] G Chir. 2008 May;29(5):230-2 [18507958.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):115-20 [12051628.001]
  • [Cites] Cancer. 1967 Sep;20(9):1438-46 [5341471.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Indian J Cancer. 1978 Dec;15(4):30-5 [757685.001]
  • [Cites] Acta Pathol Jpn. 1984 Mar;34(2):361-73 [6741549.001]
  • [Cites] Br J Surg. 1987 Mar;74(3):214-6 [3567516.001]
  • [Cites] Bull Cancer. 1990;77(2):123-36 [2180503.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2602-11 [2249200.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):725-35 [1730123.001]
  • [Cites] Cancer. 1992 Nov 15;70(10):2451-9 [1423175.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):274-8 [8454272.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):574-87 [8333556.001]
  • [Cites] Am J Surg Pathol. 1994 Mar;18(3):288-95 [8116797.001]
  • [Cites] Jpn J Clin Oncol. 1996 Aug;26(4):243-7 [8765183.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):357-64 [10375092.001]
  • [Cites] Breast Cancer. 2005;12(2):154-8 [15858449.001]
  • [Cites] Oncology. 2005;69(3):256-60 [16166814.001]
  • [Cites] Ann Surg. 2007 May;245(5):784-9 [17457172.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):233-41 [17932394.001]
  • [Cites] BMC Cancer. 2008;8:86 [18380889.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):6-13 [11815954.001]
  • (PMID = 20584320.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2903594
  •  go-up   go-down


72. McLaughlin P: Follicular lymphoma: the case for timely intervention. Expert Rev Hematol; 2009 Jun;2(3):277-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma: the case for timely intervention.
  • After decades of slow progress in the management of follicular lymphoma (FL), important strides are occurring.
  • An aim for cure is realistic and appropriate for some patients, including those with stage I-II disease, some histologic subtypes of FL (e.g., FL grade 3b) and even some relapsing patients following allogeneic stem cell transplantation approaches.
  • [MeSH-major] Lymphoma, Follicular / therapy
  • [MeSH-minor] Hematopoietic Stem Cell Transplantation. Humans. Neoplasm Staging. Radioimmunotherapy. Survival Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082969.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


73. Zhang YJ, Ren ZM, Wu QL, He ZY, Huang Y, Xia YF, Lin TY, Cui NJ: [Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas]. Zhonghua Xue Ye Xue Za Zhi; 2006 Apr;27(4):217-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas].
  • OBJECTIVE: To retrospectively analyze the treatment outcomes and prognostic factors of nasal and nasopharyngeal peripheral T cell lymphomas (PTCL) patients.
  • METHODS: One hundred and twelve patients with pathologically confirmed nasal and nasopharyngeal PTCL were included, among which 39 were CD56(+) NK/T cell lymphomas.
  • 91.1% of the patients had Ann Arbor I(E)/II(E) diseases.
  • Univariate analysis showed that favorable prognostic factors for survival were pre-treatment course > 3 months, earlier clinical stage, non NK/T lymphoma, no skin involvement, lower IPI, CR after initial chemotherapy, radiotherapy, CR after primary treatment and local tumor controlled.
  • Multivariate analysis showed that, pre-treatment course > 3 months (P = 0.011), non NK/T lymphoma (P = 0.007), CR after initial chemotherapy (P = 0.008) and radiotherapy (P = 0.000) were favorable prognostic factors for survival.
  • CONCLUSIONS: Although most nasal and nasopharyngeal peripheral T-cell lymphomas were diagnosed at early stage diseases, some of them were highly aggressive with poor prognosis, particularly CD56(+) NK/T cell lymphomas.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / therapy. Nasopharyngeal Neoplasms / therapy. Nose Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875549.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


74. Fridberg M, Servin A, Anagnostaki L, Linderoth J, Berglund M, Söderberg O, Enblad G, Rosén A, Mustelin T, Jerkeman M, Persson JL, Wingren AG: Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lymphoma; 2007 Nov;48(11):2221-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN.
  • Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) show varying responses to conventional therapy, and this might be contributed to the differentiation stage of the tumor B-cells.
  • The aim of the current study was to evaluate a panel of kinases (ZAP70, PKC-beta I and II and phosphorylated PKB/Akt) and phosphatases (PTEN, SHP1 and SHP2) known to be frequently deregulated in lymphoid malignancies.
  • De novo DLBCL cases were divided into two subgroups, the germinal center (GC) group (14/28) and the non-germinal center (non-GC) or activated B-cell (ABC) group (14/28).
  • ZAP70 and PKC-beta II were expressed in a significantly higher percentage of tumor cells in the clinically more aggressive non-GC group compared with the prognostically favourable GC group.
  • Also, the subcellular localization of PKC-beta I and II differed in DLBCL cells, with the PKC-beta I isoform being expressed in both the cytoplasm and nucleus, while PKC-beta II was found exclusively in the cytoplasm.
  • In addition, five cell lines of DLBCL origin were analyzed for protein expression and for mRNA levels of PTEN and SHP1.
  • For the first time, we show that ZAP70 is expressed in a higher percentage of tumor cells in the aggressive non-GC subgroup of DLBCL and that PKC-beta I and II are differently distributed in the two prognostic subgroups of de novo DLBCL.
  • [MeSH-major] Cell Nucleus / metabolism. Germinal Center / metabolism. Lymphoma, Large B-Cell, Diffuse / diagnosis. PTEN Phosphohydrolase / metabolism. Protein Kinase C / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism


75. He YF, Li YH, Huang HQ, Xia ZJ, Sun XF, Lin TY, Lin XB, Yuan ZY, Li ZM, Wang FH, Wang SS, Jiang WQ: [Clinical analysis of 59 cases of primary gastric non-Hodgkin's lymphoma]. Ai Zheng; 2005 Apr;24(4):475-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 59 cases of primary gastric non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: Gastrointestinal tract is the most common extranodal involvement site of non-Hodgkin's lymphoma (NHL).
  • RESULTS: Of the 59 PGNHL patients, 46 (78.0%) were in stage I/II.
  • The most common immune phenotype was B-cell lineage (46/49, 93.9%).
  • For those patients in intermediate grade (including immunoblastic cell lymphoma), there was no significant difference in the 5-year survival rate between the patients received chemotherapy plus surgery and the patients received chemotherapy alone (52.5% vs. 57.1%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820073.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


76. Uesato M, Miyazawa Y, Gunji Y, Ochiai T: Primary non-Hodgkin's lymphoma of the breast: report of a case with special reference to 380 cases in the Japanese literature. Breast Cancer; 2005;12(2):154-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the breast: report of a case with special reference to 380 cases in the Japanese literature.
  • Based on a diagnosis of malignant lymphoma by fine needle aspiration cytology, radical mastectomy with ipsilateral axillary lymph node dissection was performed.
  • Malignant diffuse large B-cell type lymphoma was diagnosed histologically according to the World Health Organization classification, and the clinical stage was II E by the Ann Arbor staging system.
  • Up to 2002, 380 cases of primary breast non-Hodgkin's lymphoma had been documented in the Japanese literature.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858449.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 25
  •  go-up   go-down


77. Leopardo D, Di Lorenzo G, De Renzo A, Federico P, Luponio S, Buonerba C, Matano E, Merola G, Imbimbo M, Montesarchio E, Rea A, Merola MC, De Placido S, Palmieri G: Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. World J Gastroenterol; 2010 May 28;16(20):2526-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of rituximab in gastric diffuse large B cell lymphoma patients.
  • AIM: To evaluate retrospectively the efficacy of rituximab plus chemotherapy in gastric diffuse large B cell lymphoma (DLBCL).
  • Patients were selected by stage (I-IV, Lugano staging system), European Cooperative Oncology Group performance status (0-2) and treatment strategies.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Stomach Neoplasms / drug therapy


78. Ho JC, Wong MP, Lam WK: Lymphoepithelioma-like carcinoma of the lung. Respirology; 2006 Sep;11(5):539-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This uncommon but distinct form of non-small cell lung carcinoma has a predilection for young non-smoking Asians, without gender distinction.
  • Among the reported cases, more than half were in early resectable stages (I or II) and there was a tendency for peribronchovascular spread with vascular encasement in advanced diseases.
  • In order to establish the diagnosis of LELC of the lung, both nasopharyngeal carcinoma and lymphoma have to be excluded by endoscopic biopsy (with or without magnetic resonance imaging of the nasopharynx) and immunohistochemical staining of the biopsy samples.
  • The mainstay of treatment for early-stage disease is curative surgical resection, whereas multimodality treatment (surgery, chemotherapy, radiotherapy) has been adopted in advanced or metastatic diseases.
  • The overall survival is more favourable in LELC of the lung compared with non-LELC type of non-small cell lung carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung / pathology. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916325.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 40
  •  go-up   go-down


79. Reece D, Imrie K, Stevens A, Smith CA, Hematology Disease Site Groupof Cancer Care Ontario’s Program in Evidence-based Care: Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline. Curr Oncol; 2006 Oct;13(5):160-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
  • QUESTIONS: In patients with multiple myeloma, Waldenström macroglobulinemia, or lymphoma, what is the efficacy of bortezomib alone or in combination as measured by survival, quality of life, disease control (for example, time to progression), response duration, or response rate?What is the toxicity associated with the use of bortezomib?Which patients are more or less likely to benefit from treatment with bortezomib?
  • A number of phase ii studies were also retrieved, including a randomized phase ii study.
  • No randomized trials were retrieved for lymphoma.
  • Bortezomib is recommended as the preferred treatment option in patients with myeloma relapsing within 1 year of the conclusion of initial treatment; it may also be a reasonable option in patients relapsing at least 1 year after autologous stem-cell transplantation.
  • PRACTICE GUIDELINE: This evidence-based series applies to adult patients with myeloma, Waldenström macroglobulinemia, or lymphoma of any type, stage, histology, or performance status.
  • RECOMMENDATIONS: Based on the results of a large well-conducted rct, which represents the only published randomized study in relapsed myeloma, the Hematology Disease Site Group (dsg) offers the following recommendations: For patients with myeloma refractory to or relapsing within 1 year of the conclusion of initial or subsequent treatment or treatments, including autologous stem-cell transplantation, and who are candidates for further chemotherapy, bortezomib is recommended as the preferred treatment option.Bortezomib is also a reasonable option for patients relapsing at least 1 year after autologous stem-cell transplantation.
  • However, evaluation of these other options is beyond the scope of this practice guideline.For patients with myeloma relapsing at least 1 year after the conclusion of alkylating agent-based chemotherapy who are candidates for further chemotherapy, further treatment with alkylating agent-based chemotherapy is recommended.Evidence is insufficient to support the use of bortezomib in patients with non-Hodgkin lymphoma or Waldenström macroglobulinemia outside of clinical trials.
  • The Hematology dsg recognizes that thalidomide is an active agent in multiple myeloma patients who have relapsed after autologous stem-cell transplantation or who are refractory to alkylating agent-based chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1986 Jul;105(1):8-11 [3717812.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Cancer. 1981 Apr 15;47(8):1923-9 [7226087.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Blood. 2004 Jul 15;104(2):336-9 [15054044.001]
  • [Cites] Blood. 2004 Aug 1;104(3):607-18 [15090448.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1386-95 [15155468.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):165-72 [15461622.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1578-82 [16342650.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1226-31 [9508211.001]
  • [Cites] Blood. 2001 Jul 15;98(2):492-4 [11435324.001]
  • [Cites] Ann Intern Med. 2002 Apr 16;136(8):619-29 [11955031.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] N Engl J Med. 1984 May 24;310(21):1353-6 [6546971.001]
  • (PMID = 22792013.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3394599
  • [Keywords] NOTNLM ; Bortezomib / Velcade / clinical practice guideline / lymphoma / multiple myeloma / systematic review
  •  go-up   go-down


80. Martinelli G, Ryan G, Seymour JF, Nassi L, Steffanoni S, Alietti A, Calabrese L, Pruneri G, Santoro L, Kuper-Hommel M, Tsang R, Zinzani PL, Taghian A, Zucca E, Cavalli F: Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. Ann Oncol; 2009 Dec;20(12):1993-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group.
  • BACKGROUND: Primary breast lymphoma (PBL) of low-grade histology is a rare disease.
  • RESULTS: We collected data on 60 cases of PBL [36 follicular and 24 marginal-zone lymphoma (MZL)].
  • Stage was I(E) or II(E) in 57 patients and IVE in three patients due to bilateral breast involvement.
  • Conversely, patients with follicular PBL had inferior PFS and OS when compared with limited-stage nodal follicular non-Hodgkin's lymphomas, suggesting an adverse prognostic role of primary breast localisation in this histological subgroup.


81. Chen DG, Yang Y, Pan CZ: [Primary mediastinal large B-cell lymphoma:a report of 24 cases with literature review]. Ai Zheng; 2008 Feb;27(2):187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mediastinal large B-cell lymphoma:a report of 24 cases with literature review].
  • BACKGROUND & OBJECTIVE: Primary mediastinal large B-cell lymphoma (PMBCL) is an uncommon subtybe of diffuse large B-cell lymphoma (DLBCL).
  • RESULTS: Of the 24 patients, 16 were men and 8 were women, aged from 12 to 81; 20 were at stage I-II, 1 at stage III, and 3 at stage IV; 13 had bulk disease; 10 had superior vena cava syndrome; 14 had contiguous infiltration; 15 had lacate dehydrogenase elevation; 11 received chemoradiotherapy, 10 received chemotherapy alone, and 3 received radiotherapy alone; 10 achieved complete remission (CR) after scheduled treatment, 12 achieved partial remission (PR), 1 had stable disease and 1 had progressive disease.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / therapy. Mediastinal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279619.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 14
  •  go-up   go-down


82. Wang XQ, Zhang LX, Bi CF, Luo TY, Lin L, Min M, Zhao Y, He GX, Feng J, Liu WP: [Primary lymphoma of breast: a clinicopathologic, immunophenotypic and prognostic study of 21 cases]. Zhonghua Bing Li Xue Za Zhi; 2010 May;39(5):302-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of breast: a clinicopathologic, immunophenotypic and prognostic study of 21 cases].
  • OBJECTIVE: To investigate the clinicopathologic and immunophenotypic features of primary breast lymphoma (PBL) and to discuss the diagnosis of the tumor.
  • According to Ann Arbor staging system, 20 cases were stage I-II (95.2%), and the remaining case was stage IV (4.8%).
  • All the cases were considered non germinal center B-cell-like type of DLBCL. (3) Follow-up data was available in 64% of the cases.
  • CONCLUSION: All the cases of PBL in the current study were DLBCL, non germinal center B-cell-like type, and a diagnosis of PBL can only be established after excluding breast involvement in systemic lymphoma.
  • [MeSH-major] Antigens, CD20 / metabolism. Breast Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654152.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Interferon Regulatory Factors; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / interferon regulatory factor-4; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


83. Jing HM, Ke XY, Dong F: [Analysis of prognostic correlated factors of 49 patients with mucosa-associated lymphoid tissue lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec;15(6):1293-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of prognostic correlated factors of 49 patients with mucosa-associated lymphoid tissue lymphoma].
  • The aim of this study was to investigate the clinical feature of mucosa-associated lymphoid tissue lymphoma and clarify the relationship between the pathological, clinical features, the expression of API2-MALT1 and the prognosis.
  • A number of factors including pathological characters, grade, stage, prognosis and treatment of 49 cases of MALT lymphoma were analyzed, and the API2-MALT1 rearrangement was detected by RT-PCR.
  • The results showed that 49 patients were diagnosed as MALT lymphoma, in which median age was 52.4 years.
  • Among 49 patients, stage I, II was 77.
  • 6%, stage III, IV was 22.4%.
  • Among 18 patients with gastric MALT lymphoma, 9 cases (50.0%) were helicobacter pylori (HP) positive and received antibiotic treatment.
  • It is concluded that MALT lymphoma is often seen in older patients, most of them were in low grade with slow progression.
  • The site, grade, stage and molecular genetic changes are important prognostic factors, which can contribute to choosing suitable treatment for patients with MALT lymphoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088487.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


84. Lenz G, Dreyling M: Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL? Nat Clin Pract Oncol; 2005 Feb;2(2):72-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Rituximab. Stem Cell Transplantation. Thalidomide / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264875.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


85. Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R: Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol; 2010 Oct;151(2):159-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
  • Peripheral T-Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission and survival rates than B-cell lymphomas.
  • The Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang (GOELAMS) devised an alternative therapeutic schedule including etoposide, ifosfamide, cisplatin alternating with doxorubicin, bleomycin, vinblastine, dacarbazine (VIP-reinforced-ABVD; VIP-rABVD) and compared it to CHOP/21 as front-line treatment in non-cutaneous PTCL.
  • Anaplastic large cell lymphoma type and Ann Arbor stage I-II were identified as two independent favourable prognostic factors influencing survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20738307.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; ABVD protocol; CHOP protocol; ICE protocol 1
  •  go-up   go-down


86. Karchenko VP, Voznyĭ EK, Belonogov AV, Bozhenko VK, Olfer'ev MA, Galil-Ogly GA: [Monoclonal antibody therapy with mabtera of patients with b-cell low grade non-Hodgkin's lymphoma]. Vopr Onkol; 2005;51(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monoclonal antibody therapy with mabtera of patients with b-cell low grade non-Hodgkin's lymphoma].
  • The data on monoclonal antibody monotherapy (mabtera, rituximab) in 44 patients with B-cell low grade non-Hodgkin's lymphoma were assessed.
  • Fever and shivering stage I and II were among the most frequent post-infusion effects.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / therapy. Lymphoma, Non-Hodgkin / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909809.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


87. Ewens KG, George RA, Sharma K, Ziyadeh FN, Spielman RS: Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes; 2005 Nov;54(11):3305-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All families had at least one offspring with diabetes and end-stage renal disease or proteinuria.
  • Nevertheless, nominally significant TDT results (P < 0.05) were obtained with polymorphisms in 20 genes, including 12 that have not been studied previously: aquaporin 1; B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene; catalase; glutathione peroxidase 1; IGF1; laminin alpha 4; laminin, gamma 1; SMAD, mothers against DPP homolog 3; transforming growth factor, beta receptor II; transforming growth factor, beta receptor III; tissue inhibitor of metalloproteinase 3; and upstream transcription factor 1.

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • MedlinePlus Health Information. consumer health - Diabetic Kidney Problems.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249459.001).
  • [ISSN] 0012-1797
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-55227
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


88. Huang WT, Chang KC, Huang GC, Hsiao JR, Chen HH, Chuang SS, Chen TY, Su WC, Tsao CJ: Bone marrow that is positive for Epstein-Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type. Haematologica; 2005 Aug;90(8):1063-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow that is positive for Epstein-Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type.
  • BACKGROUND AND OBJECTIVES: Extranodal NK/T-cell lymphoma, nasal type is an aggressive lymphoma that is always associated with Epstein-Barr virus (EBV).
  • This study was done to evaluate the use of EBV-encoded RNA-1 in situ hybridization (EBER-1 ISH) to detect occult micrometastasis in the bone marrow (BM) of patients with nasal NK/T-cell lymphoma.
  • RESULTS: Conventional morphologic examinations failed to identify any lymphoma involvement in the 23 BM specimens obtained at initial staging.
  • Only the BM EBER-1 ISH result was shown to be an independent variable predicting overall survival in stage I and II patients (p=0.027; hazard ratio for death 0.066, 95% confidence interval, 0.006 to 0.733), suggesting that EBER-1 positivity in BM is the major determinant of a poor prognosis.
  • INTERPRETATION AND CONCLUSIONS: We suggest that EBER-1 ISH should be performed on BM specimens of patients with nasal NK/T-cell lymphoma to identify the presence of EBER-1 positive cells, which appears to carry a poor prognosis.
  • Whether or not the EBER-1 positive cells in the BM of nasal NK/T-cell lymphoma patients are true tumor cells requires further study.
  • [MeSH-major] Bone Marrow Cells / pathology. Bone Marrow Cells / virology. Herpesvirus 4, Human / genetics. Killer Cells, Natural / immunology. Lymphoma, T-Cell / immunology. RNA, Viral / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Aug;90(8):1011A [16079092.001]
  • (PMID = 16079105.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral
  •  go-up   go-down


89. Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE: Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol; 2008 Jun 1;26(16):2717-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
  • PURPOSE: To assess the clinical outcome and the influence of biomarkers associated with apoptosis inhibition (Bcl-2), tumor proliferation (MIB-1), and cellular differentiation on the outcome with dose-adjusted (DA) EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) plus rituximab (R) infusional therapy in diffuse large B-cell lymphoma (DLBCL) with analysis of germinal center B-cell (GCB) and post-GCB subtypes by immunohistochemistry.
  • PATIENTS AND METHODS: Phase II study of 72 patients with untreated de novo DLBCL who were at least 18 years of age and stage II or higher.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / classification. Germinal Center / drug effects. Lymphoma, Large B-Cell, Diffuse / drug therapy


90. Huang HQ, Lin XB, Pan ZH, Bu Q, Gao Y, Wang BF, Cai QQ, Xia ZJ, Xu RH, Jiang WQ, Guan ZZ: [CEOP regimen in the treatment for non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2007 May;29(5):391-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
  • OBJECTIVE: The aim of this study is to analyse the efficacy and toxicity of CEOP regimen in the treatment of non-Hodgkin's lymphoma (NHL).
  • RESULTS: Of these 121 patients, 83 (68.6%) had B-cell NHL and 38(31.4%) peripheral T or NK-cell NHL; 55.
  • 4% (67/121) had early disease (stage I or II), and 89.3% (108/121) had IPI score 0-2.
  • CONCLUSION: Our data show that CEOP regimen combined with or without radiotherapy for the involved field is effective and well tolerated by the patients with non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Child. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Epirubicin / adverse effects. Epirubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / adverse effects. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Analysis. Thrombocytopenia / chemically induced. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892140.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  •  go-up   go-down


91. Deng G, Yang C, Chen W: [The expression of ki-67, topoIIalpha in laryngeal squamous cell carcinoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 May;19(9):396-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of ki-67, topoIIalpha in laryngeal squamous cell carcinoma].
  • OBJECTIVE: To investigate the expression of ki-67 and topo II alpha in laryngeal squamous cell carcinoma, and the relationship between its intensity and the histological grade clinical stage and lymphoma metastasis.
  • METHOD: The levels of ki-67 and topo II alpha in larynx were measured by immunohistochemical method.
  • RESULT: The positive rate of ki-67 and topo II alpha in laryngeal squamous cell carcinoma were 43.86% and 45.74%, respectively, and that in the control group were 5.66% and 5.98%, respectively.
  • The intensity of ki-67 and topo II alpha expression correlated with histological grade. topo II alpha/ki-67 has a relationship to lymphoma metastasis.
  • CONCLUSION: The intensity of ki-67 and topo II alpha expression can evaluate the histological grade of carcinoma. topo II alpha/ki-67 is an indicator of prognosis of Laryngeal Squamous Cell carcinoma.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Carcinoma, Squamous Cell / metabolism. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Ki-67 Antigen / biosynthesis. Laryngeal Neoplasms / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16075972.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


92. Schmidt AN, Robbins JB, Greer JP, Zic JA: Conjugal transformed mycosis fungoides: the unknown role of viral infection and environmental exposures in the development of cutaneous T-cell lymphoma. J Am Acad Dermatol; 2006 May;54(5 Suppl):S202-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjugal transformed mycosis fungoides: the unknown role of viral infection and environmental exposures in the development of cutaneous T-cell lymphoma.
  • We describe what appears to be the first case in which both a husband and his wife were diagnosed with large-cell transformation of MF.
  • After 10 years of having stage I MF, the wife developed tumors that showed sheets of large transformed cells with dysplastic nuclei on skin biopsies, leading to a diagnosis of transformed MF.
  • Future studies should aim to clarify the potential role of infectious agents, such as human T-lymphotropic virus I and II, cytomegalovirus, Epstein-Barr virus, and other environmental exposures, in the development of MF.
  • [MeSH-major] Cell Transformation, Neoplastic. Environmental Exposure. Marriage. Mycosis Fungoides / etiology. Skin Neoplasms / etiology. Virus Diseases / complications


93. Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, Stolte M, Morini S, Vaira D: Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol; 2010 Feb;8(2):105-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma.
  • BACKGROUND & AIMS: Different remission rates of gastric low-grade, B-cell, mucosa-associated lymphoid tissue (MALT) lymphoma have been reported after Helicobacter pylori eradication.
  • We assessed the long-term remission and relapse rates of early stage MALT lymphoma in patients treated only by H pylori eradication and identified factors that might predict outcome.
  • RESULTS: The MALT lymphoma remission rate was 77.5% (95% confidence interval, 75.3-79.7), and was significantly higher in patients with stage I than stage II(1) lymphoma (78.4% vs 55.6%; P = .0003) and in Asian than in Western groups (84.1% vs 73.8%; P = .0001).
  • Neoplasia confined to the submucosa regressed more frequently than that with deeper invasion (82.2% vs 54.5%; P = .0001); patients with lymphoma localized to the distal stomach experienced regression more frequently than those with lymphoma of the proximal stomach (91.8% vs 75.7%; P = .0037).
  • In an analysis of data from 994 patients, 7.2% experienced lymphoma relapse during 3253 patient-years of follow-up evaluation, with a yearly recurrence rate of 2.2%.
  • Infection and lymphoma were cured by additional eradication therapy in all patients with H pylori recurrence (16.7%).
  • Five (0.05%) of the patients initially cured of lymphoma developed high-grade lymphoma within 6 to 25 months of therapy.
  • CONCLUSIONS: H pylori eradication is effective in treating approximately 75% of patients with early stage gastric lymphoma.
  • Long-term follow-up evaluation of these patients is needed to detect early lymphoma relapse or progression.
  • [MeSH-major] Gastric Mucosa / pathology. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Lymphoma / complications. Lymphoma / pathology. Stomach Neoplasms / complications. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Curr Gastroenterol Rep. 2010 Aug;12(4):229-30 [20532704.001]
  • (PMID = 19631287.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


94. Pan ZH, Huang HQ, Lin XB, Xia YF, Xia ZJ, Peng YL, Cai QQ, Lin TY, Jiang WQ, Guan ZZ: [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases]. Ai Zheng; 2005 Dec;24(12):1493-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
  • BACKGROUND & OBJECTIVE: Nasal-type NK/T-cell non-Hodgkin's lymphoma (NHL) is a unique subtype with the manifestation of local necrosis, infection and fever.
  • The efficacy of chemotherapy alone is unsatisfactory; while radiochemotherapy plays some roles in the management of NK/T-cell lymphoma (NK/TCL).
  • RESULTS: Of the 93 patients, 75 (80.6%) were in stage I-II, and 18 (19.4%) were in stage III-IV.
  • The major toxicities of radiotherapy were grade I-II mucosa lesion and myelosuppression.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell. Nose Neoplasms

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351799.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; EPOCH protocol
  •  go-up   go-down


95. Tsai HK, Li S, Ng AK, Silver B, Stevenson MA, Mauch PM: Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma. Ann Oncol; 2007 Apr;18(4):672-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma.
  • BACKGROUND: Few large studies exist on the outcome of patients treated for stage I/II mucosa-associated lymphoid tissue (MALT) lymphoma.
  • PATIENTS AND METHODS: We retrospectively reviewed the records of 77 patients consecutively treated for stage I (n = 66) or II (n = 11) MALT lymphoma at our institution.
  • CONCLUSIONS: The prognosis following treatment of stage I/II MALT lymphoma is excellent.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17218489.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


96. Kay NE, Wu W, Kabat B, LaPlant B, Lin TS, Byrd JC, Jelinek DF, Grever MR, Zent CS, Call TG, Shanafelt TD: Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer; 2010 May 1;116(9):2180-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
  • Among the 33 patients enrolled, 82% were male, the median age was 65 years (9 patients were aged >or=70 years), and 64% were classified as having Rai stage III to IV disease.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2291-8 [17514743.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):479-98 [17707835.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1885-91 [17568813.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Oct;22(5):713-4; author reply 715-7 [17979574.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]
  • [Cites] Leuk Lymphoma. 2008 Jan;49(1):49-56 [18203011.001]
  • [Cites] Blood. 2008 Aug 15;112(4):975-80 [18411418.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):498-503 [19075274.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] Blood. 2001 Jul 1;98(1):29-35 [11418459.001]
  • [Cites] Br J Haematol. 2001 Aug;114(2):342-8 [11529853.001]
  • [Cites] Leukemia. 2002 Jun;16(6):993-1007 [12040431.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • (PMID = 20187101.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000585; United States / NCRR NIH HHS / RR / M01 RR000585-332094; United States / NCI NIH HHS / CA / CA095241-09; United States / NCI NIH HHS / CA / CA95241; United States / NCI NIH HHS / CA / CA113408; United States / NCI NIH HHS / CA / R01 CA095241-09; United States / NCI NIH HHS / CA / R01 CA136591; United States / NCRR NIH HHS / RR / RR000585-332094; United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / R01 CA095241
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 395575MZO7 / Pentostatin; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ NIHMS219527; NLM/ PMC2919331
  •  go-up   go-down


97. Oh SY, Ryoo BY, Kim WS, Kim K, Lee J, Kim HJ, Kwon JM, Lee HR, Ko YH, Oh SJ, Park KW, Kim HJ, Kwon HC, Nam E, Kim JH, Park YH, Lee SS, Kim HY, Park K: Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol; 2006 Nov;85(11):781-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma.
  • Nodal marginal zone B-cell lymphoma (NMZL) is a relatively uncommon type of lymphoma.
  • Fifty-three percent of the patients had localized disease (stages I and II), and 21.2% (7/33) had bone marrow involvement at presentation.
  • The significant predictive factors for PFS were performance status, advanced stage, and follicular lymphoma IPI (FLIPI) in this study.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847665.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents
  •  go-up   go-down


98. Shabani M, Asgarian-Omran H, Vossough P, Sharifian RA, Faranoush M, Ghragozlou S, Khoshnoodi J, Roohi A, Jeddi-Tehrani M, Mellstedt H, Rabbani H, Shokri F: Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma; 2008 Jul;49(7):1360-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia.
  • Over-expression of ROR1 gene, a member of the receptor tyrosine kinase family, has recently been reported in B-cell chronic lymphocytic leukemia.
  • In the present study, the expression profile of ROR1 and WT1 was investigated in different immunophenotypic subsets of B-cell acute lymphoblastic leukemia (B-ALL) patients.
  • Based on immunophenotypic results, our B-ALL patients were classified in four differentiation subsets; Pro-B (n = 7), Pre-B I (n = 29), Pre-B II (n = 13) and Immature/mature B-ALL (n = 2).
  • Our results suggest that expression of ROR1 and WT1 in B-ALL is associated with the differentiation stage of the leukemic cells.
  • [MeSH-major] Burkitt Lymphoma / pathology. Receptor Protein-Tyrosine Kinases / genetics. WT1 Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Wilms' tumor.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604725.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm; 0 / WT1 Proteins; EC 2.7.10.1 / ROR1 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Tyrosine Kinase-like Orphan Receptors
  •  go-up   go-down


99. Ypma PF, Wijermans PW, Koppen H, Sillevis Smitt PA: Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma. Neth J Med; 2006 Jul-Aug;64(7):243-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma.
  • PCD can accompany different kinds of neoplasms including small cell lung cancer, adenocarcinoma of the breast and ovary, and Hodgkin's lymphoma.
  • The search for Hodgkin's disease as concomitant disorder was then started and resulted in stage II B disease.
  • The patient was successively treated with six courses of etoposide, bleomycin, vinblastine and dexamethasone and radiotherapy, which resulted in a complete remission of the Hodgkin's disease.
  • Early recognition of the concomitant disorders (anti-Tr autoantibody disease and Hodgkin's lymphoma) is of crucial importance.
  • [MeSH-major] Cerebellum / pathology. Hodgkin Disease / diagnosis. Paraneoplastic Cerebellar Degeneration / diagnosis


100. Tsavaris N, Kosmas C, Kavantzas N, Lazaris A, Skopelitis E, Dimitrakopoulos A, Siakantaris MP, Papalambros E, Diamantis N, Patsouris E, Pangalis GA: Breast cancer following curative chemotherapy for non-Hodgkin's lymphoma and the effect of drug resistance proteins to the final outcome. A retrospective study. J BUON; 2005 Jan-Mar;10(1):71-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer following curative chemotherapy for non-Hodgkin's lymphoma and the effect of drug resistance proteins to the final outcome. A retrospective study.
  • PURPOSE: To investigate the overall survival (OS) of patients developing breast cancer (BC) after curative chemotherapy for non-Hodgkin's lymphoma (NHL) and to evaluate the possible effect on the patients' outcome of the expression of drug resistance-related proteins (P-glycoprotein-Pgp, multidrug resistance-associated protein-MRP, and multidrug resistance-related vault lung resistance protein-LRP) in BC issue.
  • PATIENTS AND METHODS: 25 female patients (median age 60 years, range 37-70) who developed BC after chemotherapy for high/intermediate grade B-cell NHL, treated with CHOP and achieving complete remission (CR).
  • A matched-pair group of de novo BC patients formed the control group.
  • In both groups 14 patients had tumor grade II; 16 were negative for steroid receptors; 17 overexpressed c-erbB-2; 14 were stage IIIA/B, and 11 stage IV.
  • There was a better response for stage IV patients in the control versus the study group (p=0.07).
  • More prolonged OS was demonstrate for patients with stage III in the control group (median 51 months) and in subgroup B (median 47 months) than in subgroup A (median 16 months; p=0.00012), as well as for patients with advanced disease (p=0.0045).






Advertisement